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DEVELOPMENT OF A POSITRON-EMITTING SURROGATE MICROSPHERE
FOR IMAGE-BASED DOSIMETRY IN YTTRIUM-90 RADIOEMBOLIZATION
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B.S., Nuclear Engineering, University of New Mexico, 1994
M.S., Nuclear Engineering, University of New Mexico, 2002
Ph.D., Engineering, University of New Mexico, 2018
ABSTRACT
Radioembolization of liver tumors using yttrium-90 (Y-90) labeled microspheres
is a proven method of treatment. The primary decay mode of Y-90 is beta-minus decay.
The electrons produced during decay deliver a cytotoxic radiation dose in a localized
volume. The radiation dose is sufficient to kill tumor cells yet spare the normal liver.
The Y-90 microspheres are delivered via a catheter that has been placed in an artery that
supplies blood to the tumor. Microspheres are injected and the blood distributes the
microspheres. The current practice involves two separate procedures. The first
procedure is an assessment of the vasculature of the liver and tumor. This assessment is
performed with radiolabeled macro-aggregated albumin particles (Tc-99m MAA). The
Tc-99m MAA is injected via a catheter placed in the same location that will be used for
the delivery of Y-90 microspheres. The distribution of the Tc-99m MAA particles is
imaged using a gamma camera. This data is used to predict the microsphere distribution
and subsequent dose to the tumor, normal liver, lungs and other organs. The data may be
used to adjust the Y-90 activity and to perform crude pre-treatment dosimetry. Accurate
pre-treatment dosimetry is largely absent.
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This study was performed to create a positron-emitting surrogate microsphere that
was close in size and shape to the Y-90 microspheres. Positron emission tomography
(PET) is superior to SPECT for activity quantification. Fluorine-18 (F-18) was chosen
for initial experiments. There were two aims of the research:
Aim 1: To develop surrogate PET microsphere. This included radiolabeling,
stability testing in vitro and stability testing in an animal.
Aim 2: To develop a computational technique to perform dosimetry with the
surrogate microsphere. PET images of the surrogate radionuclide were imported into a
Monte Carlo program. PET images were used to simulate the distribution of the Y-90
microspheres. The output of the simulation was a tomographic map of absorbed dose
from the Y-90. Validation of the image-based dosimetry was performed by measuring
known amounts of F-18 and Y-90 in a phantom. The measured dose within the phantom
was compared to the dose predicted with the Monte Carlo simulation.
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I.

Introduction

A.

Liver Anatomy and Function
The liver is one of the largest organs in the body and is the largest organ in the

abdomen. It occupies the right upper quadrant of the abdomen. The liver is unique in
that it has two major supplies of blood. In a normal liver, approximately three-quarters of
the blood supply to the liver arrives through the portal vein. This blood is from the
gastrointestinal tract and contains products resulting from digestion. A function of the
liver is the processing of the material within this nutrient-rich blood. The remaining onequarter of the blood supply to the liver arrives via the hepatic artery. This blood supply is
more oxygenated that the blood within the portal vein [1]. The two blood streams mix
within the liver and blood flows out of the liver via the hepatic veins.
Based on surface anatomy, the liver can be divided into four lobes. The largest
lobe is the right lobe while the second largest is the left lobe. Two smaller lobes are the
caudate and quadrate lobes located on the posterior liver. In the Couinaud classification,
the liver can also be divided into eight functional segments. Each segment has a blood
supply, blood outflow and biliary drainage independent from the other segments [2].

B.

Liver Cancer
In the global human population, liver cancer is a major cause of death. In 2012,

liver cancer caused an estimated 745,000 deaths. In the same year, approximately
780,000 new cases of liver cancer were diagnosed. [3].
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Cancerous tumors can be classified as primary or secondary. A primary cancer of
the liver is a cancer that arises from cells normally found in the liver. Metastasis is the
process in which a primary tumor sheds cells. These cells travel to a different location
within the body. A tumor then begins to grow at the new location. This tumor is known
as a secondary tumor or metastasis. The characteristics of the secondary tumors are
governed by the tissue type of the original tumor. The most common type of primary
liver cancer is hepatocellular carcinoma (HCC). It accounts for 70% to 90% of all
primary cancers of the liver [3].
Colorectal cancer (CRC) is a major source of metastases to the liver. In 2012,
colorectal cancer was responsible for approximately 690,000 deaths worldwide [3].
Approximately 35% to 60% of patients with CRC will develop liver metastases [4] [5].
Different types of cancers often have different characteristics relevant to imaging
and therapy. For instance, HCC tends to produce solitary tumors that are well
vascularized while colorectal metastases within the liver often present as multiple, diffuse
tumors.

C.

Methods of Treatment
Often cancer cells are rapidly dividing and thus spend a higher fraction of time in

mitosis than cells comprising normal tissue. Chemotherapy is a method of cancer
treatment that is characterized by the use of drugs that primarily inhibit cell division.
Usually these drugs are injected into the blood and the effects are system-wide. These
drugs act on cells in mitosis. Chemotherapeutic drugs may affect other cells in the body
that have a high rate of mitosis such as hair follicles and cells in the GI tract. It is
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possible to infuse chemotherapy agents directly into the hepatic artery to increase the
concentration of the chemotherapy drugs within the tumor [4].
Resection is the surgical removal of a tumor. It is possible to surgically isolate
segments and remove them without damage to the remaining segments. The degree of
tumor involvement in the liver often determines whether resection is a possible treatment
or not. Other methods of treatment include external beam radiotherapy,
chemoembolization and RF ablation.

D.

Radioembolization
Radioembolization is a method often used when patients have unresectable liver

cancer that is not responsive to chemotherapy [6]. Radioembolization has been used in
the treatment of primary and metastatic cancer in the liver [7]. This treatment takes
advantage of the difference in the blood supply to liver tumors and normal liver tissue. In
many instances, a tumor will have a blood supply that is different from the blood supply
to the normal liver. Through the process of angiogenesis, hepatic tumors are able to elicit
the growth of new blood vessels. These new vessels supply the tumor with the required
oxygen and nutrients necessary for growth. The hepatic artery contains blood that has a
greater oxygen content than blood within the portal vein. Many tumors within the liver
receive approximately 80% to 100% of incoming blood from the hepatic artery [7]. In the
normal liver only approximately 25% of the blood is supplied by the hepatic artery.
Normal liver tissue obtains the majority of blood from the portal vein.
The isotope yttrium-90 (Y-90) was an early choice for radioembolization therapy.
In 1965, yttrium-90 was used in an arterial infusion to treat liver cancer [4]. Y-90 is still
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the most widely used radionuclide for radioembolization therapy. The number of Y-90
radioembolization therapies performed in the U.S. is difficult to determine. One device
used for this therapy is approved by the FDA under the Humanitarian Device Exemption.
This limited the number of patients to 4,000 per year. In 2017, approval was granted to
increase this limit to 8,000 per year. It is likely that thousands of Y-90 radioembolization
therapies are performed each year in the U.S.
During Y-90 radioembolization, a catheter is threaded into the hepatic artery
upstream of the tumor. Radioactive microspheres labelled with Y-90 are injected into the
arterial blood stream. The microspheres are carried by the blood downstream and are
captured in the capillaries of the tumor. The disintegration of the Y-90 nuclei via betaminus decay delivers energetic electrons into the surrounding tissue. By selective
placement of the microspheres such that a majority are captured in tumor tissue, a large
absorbed dose of radiation can be delivered to tumors. The dose to the normal liver
tissue can be kept relatively low. Radioembolization therapy is often referred to as
Selective Internal Radiation Therapy (SIRT).

In some instances, Y-90

radioembolization has resulted in remission. In some cases, Y-90 radioembolization is
used to reduce the tumor size so that other methods such as surgery can be used [7].
Regardless, it is important to deliver a sufficient dose to the tumor while sparing the liver.

E.

Yttrium-90
Yttrium is a group 3 transition metal. On the periodic chart it is found between

the alkaline metal strontium, Sr, and the transition metal zirconium, Zr. Yttrium-90 is a
radioactive isotope of yttrium with a half-life of 2.6684 days ± 0.0013 days (64.0416
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hours ± 0.0312 hours) [8]. Y-90 decays to the stable ground state of Zr-90 by betaminus decay. In 99.983% of decays, the maximum energy of the beta electron is 2278.7
keV and the average energy of the electron is 926.7 keV ± 0.8 keV [8] . There are other,
low-probability decay pathways. In 0.0000014% of decays, there is a 2186 keV gamma
emitted.

Figure 1: Decay Scheme of Yttrium-90

In 0.017% of decays, the maximum energy of the beta electron is 518.0 keV and
the average energy of the electron is 163.7 keV. In this instance, the Zr-90 nucleus is left
in an excited state 1760.7 keV above ground state [9]. Occasionally, the transition from
this excited state results in internal pair production with a branching ratio of (31.86 ±
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0.47) ×10-6 [10]. The positron emission from this rare pathway has been successfully
used for Y-90 TOF PET imaging [11]–[13] .
For Y-90 decay, the average range of the electrons in soft tissue is 2.5 mm with a
maximum range of 11 mm, with 90% of the energy deposited in 5.3 mm [6]. The most
abundant cell within the liver is the hepatocyte. A typical hepatocyte is polygonal with
sides measuring approximately 25 µm to 40 µm [14]. Thus, the range of a Y-90 betaminus electron emitted with the average kinetic energy is approximately 100 cell
diameters. As the electrons slow, kinetic energy is converted into excitation and
ionization of the surrounding atoms and molecules. This deposition of energy constitutes
the absorbed dose to the tissue.
The energetic electrons emitted during decay of Y-90 can undergo bremsstrahlung
interactions within the surrounding tissue. The result is the emission of bremsstrahlung
x-rays. The energy spectrum of the bremsstrahlung is broad with a maximum energy of
2.278 MeV. The radiation yield is the fraction of kinetic energy of the primary particle
that is converted into electromagnetic radiation. From the ESTAR database published by
NIST, for electrons with kinetic energy ranging from 2000 keV to 100 keV, the radiation
yield ranges from 7.085×10-3 to 5.842×10-4 respectively [15].

F.

Y-90 Microspheres
There are two FDA approved products available for Y-90 SIRT. Both of these

products are in the form of microspheres. TheraSpheres are glass microspheres
available from BTG International Ltd. The mean sphere diameter is in the range 20 µm
to 30 µm [16] . The density of the microsphere is 3.2 g/mL [17]. Stable Y-89 is mixed
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with the borosilicate glass that makes up the microsphere. Neutron activation of the
microsphere produces Y-90. Thus, Y-90 is incorporated into the glass matrix that makes
up the microsphere. These microspheres were approved 1999 by the FDA under a
Humanitarian Device Exemption (HDE). TheraSpheres are indicated for “radiation
treatment or as a neoadjuvant to surgery or transplantation in patients with unresectable
hepatocellular carcinoma (HCC) who can have placement of appropriately positioned
hepatic arterial catheters.” [16].
SIR-Spheres are resin microspheres available from Sirtex Medical Inc. The
diameter of the microspheres is 20 µm to 60 µm [18] The density of the resin
microspheres is 1.6 g/mL [17]. The resin microspheres were approved by the FDA in
2002. In this case of the resin microspheres, the Y-90 is primarily bound to the surface of
the resin microsphere. The surface chemistry and composition of SIR-spheres are
proprietary [19].
The Y-90 microspheres are not detectable with clinically used x-ray modalities,
MRI or sonography. Y-90 does not emit significant gamma radiation and cannot be
imaged using typical nuclear medicine techniques. Therefore the choices for imaging Y90 microspheres in vivo are limited. The options for clinical imaging of Y-90 include
imaging bremsstrahlung x-rays with a gamma camera. The bremsstrahlung images tend
to be of poor quality. Another method of clinical imaging utilizes Y-90 Time-of-Flight
Positron Emission Tomography (Y-90 TOF PET). However, the number of positrons
emitted by Y-90 emitted is low.
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Figure 2: Post-therapy imaging of the same patient. Bremsstrahlung SPECT is on the left, Y-90 TOF PET
is on right. Bremsstrahlung image has less spatial resolution and poorer contrast that TOF PET.

G.

The Dosimetry of Y-90 Microspheres
The resin and glass Y-90 microspheres are permanent implants and are not

expected to be removed from the body once implanted. The biological elimination of
radioactivity is non-existent. The only means of elimination of radioactivity is through
physical radioactive decay of the Y-90. The time-integrated activity in the source is
given by the following equation.

∞

𝐴̃ℎ = ∫ 𝐴ℎ (𝑡)𝑑𝑡

(1.1)

0

This is the activity integrated from the calibration time, t = 0, to time equals
infinity, t =. In the MIRD schema, 𝐴̃ℎ is the cumulated activity in organ h. This is the
total number of disintegrations that occur in organ h. The total number of disintegrations
of Y-90 occurring in the implanted microspheres is given by the equation:
8

𝐴̃ℎ = 𝐴0 ∙ 𝑇1/2 ∙

1
ln(2)

(1.2)

The term, A0, is the activity at the calibration time, t = 0 and T1/2 is the half-life of
Y-90. The half-life of Y-90 is 2.6684 days. For an initial activity of 1 GBq of Y-90, the
cumulated activity, 𝐴̃ℎ is:

𝐴̃ℎ = (1x109 disintegrations/sec) x [(2.6684 days)(86400 sec/day)] x [1/ln(2)]
= 3.326x1014 disintegrations

The total energy released as kinetic energy of the electrons during beta minus
decay is given by the cumulated activity multiplied by the average kinetic energy of the
electrons, 926.7 keV.

Total K.E. = 3.326x1014 disintegrations x 926.7 keV/disintegration
= 3.082x1017 keV

To calculate the absorbed dose to tissue assume that radiative energy loss due to
bremsstrahlung is negligible.

(3.082x1020 eV) x (1.60218x10-19 Joule/eV)
= 49.38 Joules per GBq
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A value of 49.38 ± 0.05 Joules per GBq has been published [8]. The authors
state that the statistical uncertainties in the published values were taken into account.
The absorbed dose in tissue can be found using the following equation:

𝐽
𝐴0 (𝐺𝐵𝑞)
∙
𝐺𝐵𝑞 𝑀𝑎𝑠𝑠(𝑘𝑔)

𝐷𝑜𝑠𝑒(𝐺𝑦) = 49.38

(1.3)

Where A0 is the initial activity of the Y-90 microspheres in tissue and the mass
term describes the mass of tissue into which the kinetic energy is being deposited.

H.

Current Methods in Y-90 Radioembolization
Y-90 radioembolization therapy generally follows a course of action comprised of

a pre-treatment mapping phase and a treatment phase. The performance of these two
phases is often separated by approximately two weeks. A schematic of the actions
involved in radioembolization therapy are shown in the graphic below.
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Figure 3: Schematic timeline of radioembolization therapy

I.

Angiography and coil embolization
Prior to administration of the Y-90 microspheres, a careful evaluation of the

hepatic vasculature is performed. Special attention is placed on the hepatic artery and
associated vessels in the vicinity of the lobe or segment that is to be treated. Using
fluoroscopy for guidance, a catheter is inserted into the vasculature supplying blood to
the liver and tumor. Angiography with iodine contrast is then performed to investigate
the patient-specific vasculature. A goal of this evaluation is to identify and isolate the
arterial blood supply to the tumor. In addition, it is necessary to identify nearby vessels
that supply blood to non-target areas such as the stomach, duodenum, pancreas and gall
bladder. In some instances, embolization coils are used to occlude vessels to non-target
areas. [2]. Serious complications can occur if Y-90 microspheres deposit in some of
these areas. Abnormal vascular anatomy that has a high probability of producing reflux
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of microspheres into non-target areas such as the stomach, pancreas and bowel is a
contraindication for the administration of SIR-Spheres [18].

J.

The Use of Tc-99m MAA

After angiography and coil embolization, a catheter is placed into the location that will be
used in the future for the administration of Y-90 microspheres. At this time, the catheter
is used to administer approximately 4 mCi of Tc-99m Macro Aggregated Albumin
(MAA) [16], [18]. Albumin is a protein found in blood plasma. In the form of MAA, the
albumin forms irregularly shaped aggregations of particles. The MAA size distribution
does not match the size distribution of the microspheres. The package insert for
TechneScan MAA (Malliinkrodt) states that 90% of the particles are between 10 to 40
microns and that no particle is greater than 150 microns [20]. Thus, the shape and size of
typical MAA particles do not match the shape and size of the Y-90 microspheres. If
shape and size are important to the particle distributions, then a difference in the MAA
distribution and the Y-90 microsphere distribution may be expected.
The infusion rate of the Tc-99m MAA is dependent upon the user. The infusion
of MAA may simulate the infusion of Y-90 microspheres[2]. No study has compared the
infusion Tc-99m MAA and Y-90 microspheres. After the infusion, the catheter is
removed. Once the patient is stabilized, they are moved to the nuclear medicine
department where the Tc-99m MAA distribution is imaged using a gamma camera. Tc99m is a commonly used radionuclide that decays by isomeric transition during which a
140 keV gamma photon is emitted. There are three purposes for imaging the distribution
of Tc-99m MAA:
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1. Evaluate shunting of particles to the lungs
2. Evaluate shunting to extrahepatic sites other than the lungs
3. Adjustment of administered activity
The distribution of the Tc-99m MAA is often used to adjust the amount of Y-90
that will be given during the therapeutic administered of the Y-90 microspheres [6] [18],
In this instance, the Tc-99m MAA is being used as a surrogate particle for Y-90 and is
being used to adjust the administered activity.

K.

Evaluation for Lung Shunting
Arteriovenous shunting within the tumor may occur as a result of the modification

of vessels by the tumor. Blood bypasses capillary beds through the modified vessels.
This decreases the likelihood of microsphere deposition within the tumor. The result is
that the blood-borne microspheres are “shunted” to the next major biological filter which
is the lungs.
The fractional lung shunting is evaluated by measuring the relative amounts of
Tc-99m activity in the lungs and liver. Using the images obtained with the gamma
camera, a Region of Interest (ROI) is drawn around the lungs. The number of counts in
the lung ROI is recorded. The amount of activity in the liver is measured by drawing a
ROI around the liver and measuring the counts in the liver. The percent lung shunt is then
calculated using the following formula:

𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝐿𝑢𝑛𝑔 𝑆ℎ𝑢𝑛𝑡 = 100% ×

𝐿𝑢𝑛𝑔 𝐶𝑜𝑢𝑛𝑡𝑠
(𝐿𝑢𝑛𝑔 𝐶𝑜𝑢𝑛𝑡𝑠 + 𝐿𝑖𝑣𝑒𝑟 𝐶𝑜𝑢𝑛𝑡𝑠)
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(1.4)

Figure 4: Lung shunt study with Tc-99m MAA. Regions of Interest (ROIs) are drawn in red around the
liver and lungs. The number of events (counts) in each ROI is used to calculate the fraction of injected Tc99m MAA that deposited within the lungs.

A “count” is a recorded event in which the gamma camera detected a gamma
photon of interest. In this case, the gamma photons of interest are the 140 keV photons
emitted by Tc-99m. The SIR-Sphere package insert recommends that anterior and
posterior images of the thorax and abdomen are acquired with a large Field-of-View
(FOV) gamma camera [18]. The recommendation also states that each image should
contain between 7x105 to 1x106 counts.
14

To reduce the risk of radiation-induced pneumonitis the absorbed dose to the
lungs must be kept at or below 30 Gy [18]. The percent lung shunt will be used to
calculate and modify the amount of Y-90 SIR-Spheres that are administered to the
patient. A significant amount of shunting may form the basis for denying the patient Y90 therapy. SIR-Spheres are contraindicated for lung shunting in excess of 20% [18].
Likewise, for TheraSpheres it is necessary to keep the absorbed dose to the lungs at or
below 30 Gy. The TheraSpheres package insert states the shunting of Y-90 microspheres
to the lungs must be less than 16.5 mCi (0.61 GBq) [16].
There is evidence that Tc-99m MAA significantly degrades after injection [21]
[22]. Two groups of researchers found that compared to lung shunt fractions measured
early after administration, there was an increase in lung shunt fractions measured later
(>4 hours) after administration. In one study, three patients had lung shunt fractions that
were between 7% and 8% at the 1 hour post-administration time. At the >4 hour postadministration time, all three patients had measured lung shunt fractions in excess of 20%
[22]. In these cases, the late lung shunt measurements could have resulted in
misappropriate reduction in the administered activity of Y-90 microspheres or
misappropriate exclusion from the treatment altogether.
Radioactive microspheres in locations such as the GI tract, pancreas or gall
bladder can create problems. For instance, Y-90 microspheres in the GI tract can result
in ulceration and bleeding. The deposition of microspheres in extrahepatic locations is
often not due to intra-tumor shunting but is due to unplanned flow of microspheres into
the arterial supply of the extrahepatic location. This is usually prevented by placing
embolic coils prior to administration of the microspheres. A problem seen with the
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degradation of the Tc-99m MAA is the creation of free technetium ion. The
biodistribution of free technetium includes the stomach. The uptake of free Tc-99m in
the stomach can mimic or mask the deposition of Tc-99m MAA particles in the stomach.

L.

Adjustment of Administered Activity
Another purpose of the administration of Tc-99m MAA is to use the MAA as a

surrogate particle for the prediction of the Y-90 dose deposition within the liver. The
assumption is that the Tc-99m MAA will go to the same location in the normal liver and
tumor as the Y-90 microspheres. However, the validity of this assumption is
questionable. In some instances, the distribution of Tc-99m MAA has been shown to be
a poor predictor of the Y-90 microsphere distribution [23]. Regardless, the distribution
of Tc-99m MAA within the liver is used to make adjustment to the administered dose.
To a certain degree this may be considered treatment planning. Compared to treatment
planning methods used in external beam therapy and brachytherapy, the methods
discussed below are crude and lack accuracy.

1.

SIR spheres
In early versions of the package insert for SIR Spheres, there were two methods

for calculating the amount of Y-90 to be administered to the patient [24]. These methods
were the empirical model and the partition model. The latest version of the package
insert now recommends using the Body Surface Area method for calculating the Y-90
activity to administer to the patient[18]. The empirical model is included for
completeness.
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a)

The Empirical Method

In early clinical trials, this method was used to determine the activity of SIRSpheres microspheres to be used. The empirical method was “abandoned after clinically
observed toxicity”[6].

In the empirical method, the recommended amount of Y-90

activity to be administered was 2 to 3 GBq based on the percent involvement by the
tumor in the liver. The amount of involvement by tumor was measured with CT or MRI
[7]. For greater than 50% tumor involvement, the recommended activity is 3 GBq. For
25% to 50% involvement, the recommended activity is 2.5 GBq. For less than 25%
involvement, the recommended activity is 2.0 GBq. The degree of lung shunting further
modified the amount of administered activity.

b)

Partition Method

Of the methods commonly used to modify the activity to be administered to the
patient, the partition model is the most complex and most accurate. [25]. The partition
model was proposed in 1996 by Ho et al.[26]. The partition model is based on the
assumption that the distribution of Tc-99m MAA particles will be the same as the
distribution of Y-90 microspheres. Another assumption is that the particles will be
distributed among three compartments, the lungs, normal liver tissue and tumor. The
three equations that follow are similar to the equations first introduced in the paper by Ho
et al.
The activity that goes to the lungs, AL, due to shunting can be expressed as:
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𝐴𝐿 = 𝐴 × (

𝐿
)
100

(1.5)

Where A is the total administered activity and L is the percent of administered
activity that goes to the lungs. The measurements required to calculate the percent lung
shunt were described earlier.
The activity that does not go to the lungs is divided among the tumor and normal
liver. The relationship between the three compartments can be written as:

𝐴𝑇 + 𝐴𝑁 = 𝐴 × (1 − (

𝐿
))
100

(1.6)

Here the activity in the tumor is AT and the activity in the normal liver is AN.
The tumor-to-normal tissue ratio of uptake of Tc-99m MAA in the liver, T/N, is
given by:
𝐴𝑇
𝑇 (𝑀𝑇 )
=
⁄𝐴
𝑁
(𝑀𝑁 )
𝑁

(1.7)

This ratio is the activity per unit mass of tumor divided by the activity per unit
mass of normal liver tissue. The mass of the tumor, MT, and the mass of the liver, MN,
can be measured using CT or other tomographic modality. The tumor-to-normal tissue
ratio (T/N) is measured from the distribution of Tc-99m MAA. The equations can be
solved simultaneously for AT and AN.

Once the activity in the tumor and the activity in

the normal liver is determined, the absorbed dose to both regions can be calculated using:
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𝐽
𝐴0 (𝐺𝐵𝑞)
∙
𝐺𝐵𝑞 𝑀𝑎𝑠𝑠(𝑘𝑔)

𝐷𝑜𝑠𝑒(𝐺𝑦) = 49.38

(1.3)

The partition model can be used to calculate the activity that needs to be
administered to deliver a prescribed radiation dose to the tumor. Likewise, the partition
model can be used to calculate the maximum activity that can be administered while
keeping the radiation dose to the lungs or normal liver tissue below a desired value.
The estimated T/N is performed with the surrogate Tc-99m MAA particles. The
true T/N ratio can only be measured after the administration of Y-90 microspheres [25].
Ho made measurements of the Y-90 distribution using a detector to measure beta activity
during laparotomy [26]. A more modern, less invasive approach is to measure the posttreatment Y-90 distribution using Y-90 PET imaging [25].
For the partition model to be valid, the assumption is made that the T/N ratio is
the same for the Tc-99m MAA and the Y-90 microspheres for all parts of the liver. The
distribution of Tc-99m MAA within the three compartments should match the
distribution of Y-90 microspheres. Any mismatch between the two distributions will
result in a loss of accuracy in the estimated dose from Y-90. The greater the degree of
mismatch, the greater is the inaccuracy in the calculated dose.
In 2012, a group of experts compared the various means of determining the
activity to be given to the patient [7]. They concluded that for resin microspheres, the
partition method was the method of choice except in the case of small tumors with
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diffuse margins. In these instances the BSA method was recommended. The group
stated, “Thus, relatively few metastases will qualify for partition model planning” [7].
The use of a PET labeled surrogate and the expected improvement in image
quality and quantification may enable better T/N ratio determination for small tumors
than what is currently possible. The ability of the new positron emitting surrogate
particles to estimate the true T/N ratio is beyond the scope of this dissertation. The
predictive accuracy of a new surrogate particles will have to be determined by use in
clinical trials. The goal of this project is to develop the tool not to evaluate its clinical
usefulness.

c)

Body Surface Area (BSA) Method

The Body Surface Area (BSA) method does not take into account the tumor-tonormal liver (T/N) ratio [25]. Instead the method relies upon the body surface area of the
patient and the measured volumes of the liver and tumor. This method is the only
recommended method in the most recent (Feb. 2017) version of the SIR-Spheres package
insert [18]. Supposedly, the liver volume correlates with the body surface area [6] [7]
[18].
For SIR-Spheres, the prescribed activity for the whole liver or bilobar treatments
can be calculated using the BSA method with following formula:

𝑃𝑟𝑒𝑠𝑐𝑟𝑖𝑏𝑒𝑑 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 (𝐺𝐵𝑞) = (𝐵𝑆𝐴(𝑚2 ) − 0.2) + (

Where BSA is given by the formula:
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𝑉𝑇𝑢𝑚𝑜𝑟
)
𝑉𝐿𝑖𝑣𝑒𝑟

(1.8)

𝐵𝑆𝐴 = 0.20247 × (ℎ𝑒𝑖𝑔ℎ𝑡(𝑚))

0.725

× (𝑤𝑒𝑖𝑔ℎ𝑡(𝑘𝑔))

0.425

(1.9)

VTumor is the volume of tumor in the liver. VLiver is the total volume of the liver
which includes non-tumor liver and tumor [18]. In this case, the liver volume would
need to be measured with CT or MRI.
If visible tumors are present in only one lobe, the recommendation is to
administer the microspheres to that lobe only. This would confine the radiation dose to
the lobe with the tumor.
There is a further modification to the BSA calculations for lobar treatments.

𝑃𝑟𝑒𝑠𝑐𝑟𝑖𝑏𝑒𝑑 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 (𝐺𝐵𝑞)
= [(𝐵𝑆𝐴(𝑚2 ) − 0.2) + (

𝑉𝑇𝑢𝑚𝑜𝑟
𝑉𝐿𝑜𝑏𝑒
)] × (
)
𝑉𝐿𝑜𝑏𝑒
𝑉𝐿𝑖𝑣𝑒𝑟

(1.10)

Where VLobe is the volume of the affected lobe. The other variables remain the
same.
There is mention in the literature that there is “no known association correlating
BSA with liver volume, tumor volume or radiation sensitivity.” [27].

2.

MIRD Method (glass microspheres)
For TheraSpheres, the recommended method of calculating the activity to

administer the patient is based on the MIRD (Medical Internal Radiation Dose)
methodology. This method is based on the assumption of a homogeneous distribution of
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activity within the liver [28]. The method in the TheraSpheres package insert uses an
energy deposition of 50 joules per kilogram of tissue for every GBq of Y-90
administered. The nominal target dose to the liver is between 80 Gy to 150 Gy [16]. To
calculate the required amount of activity to deliver this dose, the TheraSpheres package
insert has the following equation:

𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 𝑅𝑒𝑞𝑢𝑖𝑟𝑒𝑑(𝐺𝐵𝑞)
𝐷𝑒𝑠𝑖𝑟𝑒𝑑 𝐷𝑜𝑠𝑒(𝐺𝑦) × 𝐿𝑖𝑣𝑒𝑟 𝑀𝑎𝑠𝑠(𝑘𝑔)
=
50

(1.11)

The liver volume and mass can be found with CT or other modality. The package
insert also has a formula for calculating the dose to the liver after administration:

𝐷𝑜𝑠𝑒(𝐺𝑦) = 50 ×

𝐼𝑛𝑗𝑒𝑐𝑡𝑒𝑑 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦(𝐺𝐵𝑞) × (1 − 𝐹)
𝐿𝑖𝑣𝑒𝑟 𝑀𝑎𝑠𝑠(𝑘𝑔)

(1.12)

The term, F, is the lung shunt fraction. The recommended upper limit of activity
that can be shunted to the lungs is 0.61 GBq. This activity corresponds to a dose of
approximately 30 Gy using the assumption that the mass of both lungs is 1 kg [16].

0.61 GBq x 50 Gy/GBq = 30.5 Gy

Thus the upper limit of dose to the lungs from TheraSpheres is approximately the
same as the upper limit recommended for SIR-Spheres, 30 Gy. This method does not
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take into account difference in uptake between tumor and normal tissue. Beyond
adjustment for liver mass, there is no adjustment for patient-specific parameters such as
the T/N ratio.

M.

Pre-Treatment Dosimetry
While, Tc-99m MAA can be used for crude treatment planning, it will be

worthwhile to create a new surrogate that is better than Tc-99m MAA. An improvement
in pre-treatment imaging and mapping of the likely Y-90 distribution would provide data
for better treatment planning and dosimetry. Better data enables the improvement of tools
such as dose volume histograms (DVH) which are currently not being used with Tc-99m
MAA pre-treatment imaging. Improved pre-treatment imaging may also help identify
factors that may correlate to better Y-90 delivery and patient outcomes. High quality pretreatment data can help avoid delivery of toxic levels of radiation to the normal liver
parenchyma and simultaneously help avoid under-dosing the tumor.
Advancement in image-based dosimetry can enable more advanced treatment
planning techniques such as fractionation. It has been shown that the Y-90 microspheres
deposit in the outer layers of some tumors [29]. The concentration of microspheres in the
outer layers can be many times that found in the core. Thus, the outer shell of the tumor
receives the largest radiation dose. Fractionation is the planned delivery of multiple
doses or “fractions” over time and is commonly used in external beam radiation therapy.
A fraction is a delivered dose which kills the cells in the outer layer of the tumor. The
tumor size is then reduced and simultaneously the hypoxic core receives more oxygen.
Cells that are well oxygenated tend to be more radiation sensitive. At a planned point in
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time, another fraction of radiation is delivered. In this way, the tumor is reduced through
a systematic application of radiation over time until the entire tumor is destroyed. The
development of a new surrogate microsphere may provide pre-treatment dosimetry
adequate for fractionation using Y-90 microspheres.

N.

Matching Distributions of Surrogate and Therapy Particles
The accuracy of pre-treatment dosimetry depends on accurately predicting the Y-

90 microsphere distribution. There have been several investigations into the predictive
value of Tc-99m MAA for Y-90 microsphere distribution.
In one study by Ilhan et al., the authors compared the predictive value of Tc-99m
MAA SPECT for more than 500 patients with a variety of tumor types [30]. The
researchers graded tumor uptake in pre-treatment Tc-99m MAA SPECT and posttreatment Y-90 bremsstrahlung SPECT and placed them into one of four grades. The
metric used for tumor uptake was the Tissue to Background Ratio (TBR).
The grade 1 tumors had uptake that was homogeneously greater than the uptake in
the normal liver tissue. Grade 2 lesions had heterogeneous uptake that was greater than
the uptake in the normal liver tissue. Grades 3 and 4 were uptake in tumor tissue that was
equal to or less than normal liver tissue respectively. Statistical tests were used to assess
the differences between the Tc-99m MAA SPECT and Y-90 bremsstrahlung SPECT. In
general, most lesions that had a high Tc-99m MAA uptake also had a high Y-90 uptake.
Greater than 90% of the lesions studied had a high uptake with a grade of 1 or 2. Of the
57 patients that had a low Tc-99m MAA uptake of 3 or 4, 67% of these patients had a
grade 1 or 2 high uptake of Y-90 microspheres. The study recommended that patients
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should not be excluded from radioembolization based on a low pre-therapy Tc-99m
MAA uptake [30].
In another study by Wondergem et al., the authors did a retrospective analysis on
patients who had Y-90 radioembolization therapy [23]. They measured the agreement of
Tc-99m MAA SPECT and Y-90 bremsstrahlung SPECT distributions. They did this by
normalizing the Tc-99m MAA distribution to the total administered activity of Y90. They then used Bland-Altman analysis to compare the two activity distributions.
The authors claim that this is the statistical method of choice when comparing the
performance of two instruments measuring the same quantity. They concluded that the
Tc-99m MAA distribution did not accurately predict the distribution of Y-90
microspheres. They also identified factors that may have contributed to the mismatch
between the distributions. The authors also mention that using Y-90 PET instead of Y-90
bremsstrahlung SPECT could improve post-treatment quantification.
Another group, Jiang et al., investigated catheter placement and segmental
perfusion differences between MAA and Y-90 distributions [2]. They looked at factors
including the difference in catheter placement, the proximity to a bifurcation and
proximity to a side artery. The found a high degree of correlation. They also pointed out
that the particle size, shape, and density play a role in causing a difference in particle
distributions.
Another study was performed by Gnesin et al. to examine the agreement between
pre-therapy Tc-99m MAA SPECT/CT dosimetry with post-therapy Y-90 TOF PET/CT
for resin and glass microspheres. [11]. They created voxelized dose maps from the Tc99m MAA SPECT/CT and the Y-90 TOF PET. The dose gold standard was the
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voxelized dose map produced by the Y-90 TOF PET/CT. The dose map obtained from
the Tc-99m MAA SPECT was compared to the baseline dose map produced from the Y90 TOF PET. The comparison was done for tumor volumes and non-tumor volumes. The
agreement between the dose maps was measured using a statistical metric known as the
Lin concordance. The conclusion was that Tc-99m MAA SPECT/CT provided good
estimates of the absorbed doses from Y-90. The agreement between the MAA and Y-90
dose maps was much better for tumors larger than 150 mL [11]. A sphere with a volume
of 150 cm3 has a radius of 3.3 cm. The use of a surrogate PET microsphere and superior
resolution of PET imaging would likely produce good agreement with smaller volumes.

O.

Factors That May Affect the Predictive Value of Surrogate Particles
The following factors may affect the predictive value of surrogate particles and

may be important in the mismatch between Tc-99m MAA distribution and Y-90
microsphere distribution:

1.

Factors dependent on operator or patient:


Distance between the Tc-99m MAA administration and subsequent Y-90
microsphere administration. Researchers have found that in some cases
the distance between the two injections could be greater than 5mm [2].



Distance from catheter to bifurcation. The distance to a bifurcation of the
artery was important [2].
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The angle of the catheter in the vessel lumen. The angle of the catheter in
the vessel can change the flow dynamics of the blood in the vicinity of the
catheter [23].



Differences in rates of injection and rhythm of injection between Tc-99m
MAA and Y-90 microsphere injections may lead to mismatch [2].



The length of the procedure and the number of interventions may increase
the likelihood of vasospasm and vasoconstriction. This will alter blood
flow pattern.

2.

Factors dependent on technical parameters:


The size of the surrogate particles should closely match the size of the
therapy microspheres. Ideally, the size of the surrogate particles and the
therapy microspheres will be identical.



The density of surrogate particle may be important. It is not entirely clear
how dependent the deposition is to microsphere density. The surrogate
particles may perform adequately even if the density is not the same as
therapy microspheres.



The shape of the surrogate and therapy microspheres should be nearly the
same. The Y-90 microspheres are spherical whereas MAA particles tend
to be irregularly-shaped random aggregations.



The surface chemistry of the surrogate is likely important. The surrogate
should readily bind to the labeling radionuclide. It should not bind to
vessel walls or to similar particles to form aggregations. Clusters and
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aggregations of microspheres could lodge near the catheter or other
locations which would lead to mismatch.


Imaging modality affects image quality and quantification. Poor
resolution and contrast recovery can lead to mismatch.



The activity per microsphere may alter the predictive value of the
surrogate particles. For resin SIR-Spheres the activity per microsphere is
50 Bq. For glass TheraSpheres the activity per microsphere is
approximately 2500 Bq. It requires significantly more resin microspheres
to achieve a target dose. A large number of microspheres has a greater
likelihood of changing the blood flow during administration and altering
the final distribution. In addition, the embolic effect may ultimately
reduce oxygen and effectiveness of the radiation delivered to the tumor.



Degradation of surrogate over time can cause a change in the distribution
pattern. For instance, the degradation of MAA may alter the distribution
of the activity over time. Thus, the predictive value of Tc-99m MAA as a
surrogate for the Y-90 is likely changing with time. The degree of the
change and the clinical impact is usually unknown.

P.

Development of Surrogate Microspheres
Effort has been placed into finding a suitable surrogate microsphere for pre-

therapy treatment planning. A brief survey of different investigations is presented here.
A promising F-18 resin surrogate was developed [19]. However, in vivo
leaching of the F-18 was a problem. The instability of the radiolabel may have been
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especially difficult to overcome since the microsphere resin material was proprietary.
The details of the surface chemistry were not well known.
Microspheres made of poly(L-lactic acid), PLLA, embedded with Holmium-166
have been developed [23] [31]. Holmium-166 has a half-life of 26.8 hours and emits
beta-minus electrons. The maximum energy of the electrons is 1.85 MeV. Holmium also
emits gamma photons with and energy of 80.6 keV which is easily imaged with a gamma
camera. Holmium-166 is also paramagnetic which enables imaging with MRI. The Ho166 PLLA microspheres can be used for both pre-treatment imaging and therapy [31].
The strategy in which the same microsphere is used for both pre-treatment
imaging and therapy has been investigated by Verger et al. In their work they use starchbased microparticles as vehicles for Tc-99m, Ga-68 and Re-188 [32]. When SPECT will
be used for pre-treatment imaging, the starch-based microparticles are labeled with Tc99m. The microparticles can be labeled with Ga-68 for PET imaging prior to treatment.
The starch-based microparticles can then be labeled with Re-188 to form the therapeutic
microparticles. Re-188 decays by beta-minus decay with a half-life of 16.98 hours. The
beta-minus electron has a maximum energy of 2.1 MeV. Re-188 also emits a gamma
with an energy of 155 keV. This can be readily imaged with a gamma camera.
An issue regarding the adoption of a surrogate replacement for Tc-99m MAA is
that MAA is specified in the package insert and is the accepted method for performing
the evaluation for lung shunting and extrahepatic deposition. The transition from Tc-99m
MAA to a new surrogate may be easier if it demonstrated that co-injection of both
particles is possible. Co-injection would enable the clinical demonstration of the
microsphere in parallel to the current method of using Tc-99m MAA for evaluation of
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shunting and adjustment of the administered activity. It may be worthwhile to investigate
whether a small amount of positron emitter will interfere with Tc-99m MAA lung shunt
measurements. If the positron-emitting isotope does interfere the Tc-99m MAA
measurements, then determination of the magnitude of the interference should be
determined. Ideally, the activity of the positron emitter would be such that this activity
would be low enough to not affect the Tc-99m measurements yet would be large enough
that PET data could be acquired to be useful for dosimetry.

Q.

Post-Therapy Imaging and Dosimetry
A potential application for a positron emitting surrogate microsphere is in post-

therapy dosimetry. One method of performing post-therapy dosimetry is done by
imaging bremsstrahlung emission with a SPECT camera. The bremsstrahlung x-rays are
emitted as the Y-90 beta minus particle slows in tissue. The energy spectrum of the
emitted bremsstrahlung x-rays is broad and the image quality is poor (see Figure 2).
Good quantification accuracy based on bremsstrahlung imaging is difficult to achieve due
to the poor spatial resolution which is on the order of centimeters. An alternative to
bremsstrahlung imaging is Y-90 Time-of-Flight (TOF) PET. Y-90 TOF PET has been
shown to be superior to bremsstrahlung SPECT for post-therapy image-based
dosimetry[33].
There are several issues with Y-90 TOF PET imaging. Positron-electron pair
formation during the decay of Y-90 is relatively rare. Approximately 32 positronelectron pairs are formed for every million decays. Thus, the count rate from Y-90 is
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low. Useful Y-90 TOF PET imaging requires large activity, relatively long counting
time, or increased detector sensitivity.
The materials that are used to make the PET scanner, may be radioactive. When
performing Y-90 TOF PET, there are background sources that are typically ignored when
performing PET with other radionuclides. LSO and LYSO are commonly used lutetiumcontaining scintillation crystals used in PET scanners. Approximately 2.6% of the
lutetium in LSO is Lu-176 which decays by beta-minus decay. The beta-minus decay is
accompanied by coincident gamma emissions at 307, 202 and 88 keV [34]. The lutetium
background can typically be ignored except when imaging with very low count rates such
as in Y-90 PET. Other sources of random coincidences include coincidences with highenergy bremsstrahlung produced by slowing beta-minus electrons.
A possible method of enhancing post-therapy PET imaging is the use of surrogate
microspheres that emit large amount of positrons. These could be co-injected with the Y90 therapy microspheres and “boost” the positron signal for PET imaging.
If the specific activity is high enough then a relatively few surrogate microspheres
would be needed to achieve the desired increase in positron emissions. Fewer surrogate
microspheres injected translates into less likelihood of inducing an embolic effect. A
microsphere labeled with a high-yield positron emitter could potentially produce on the
order of 104 more positrons than a Y-90 labeled microsphere of the same activity. The
increase in positron counts could overcome problems associated with the very low count
rates found in Y-90 TOF PET.
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The poor performance of current methods also limits the ability to accurately
measure the radiation dose delivered to the tumor tissues and normal tissues. This affects
the post-therapy assessment of delivered dose and correlation with treatment outcomes.

R.

Development of Positron-Emitting Surrogate Microsphere

1.

Choice of Radionuclide
The inclusion of Positron Emission Tomography (PET) imaging for pre-treatment

dosimetry requires the selection of a positron emitting radionuclide to label the surrogate
microspheres. Properties of the radionuclide that need to be considered include half-life,
toxicity, binding properties, and availability. In addition, the characteristics of the
emitted radiations is very important. A pure positron emitter is more desirable than a
positron emitter that has coincident gamma emissions. Coincident gamma emissions may
be mistaken for true counts during PET acquisition leading to noisy images.
Fluorine-18 is the most widely used radionuclide in PET. Thus, it has an existing
distribution network and is readily available to PET imaging centers. Fluorine-18 has a
half-life of 109.77 minutes[35], [36]. The half-life is long enough to allow for transport
and preparation of microspheres. The half-life is short enough that activity from clinical
imaging will be gone within 24 hours. F-18 emits a positron in 96.8% of decays [9].
Thus, the photon abundance for 511 keV is 2 × 96.8% or 193.6%. The mean energy of
the positron is 249.5 keV while the maximum energy is 634 keV [9]. The mean range of
the positron in water is 0.64 mm and maximum range is 2.3 mm [37]. The range in water
is relatively small compared to other positron emitters. This is a desirable feature. A
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long-range positron is likely to travel farther from the parent nucleus before undergoing
positron-electron annihilation. As the positron travels from the point of origin, the
uncertainty regarding the location of the point of origin increases. This manifests as a
contribution to image blur in PET. As the positron range increases, the resulting image
blur increases and spatial resolution decreases.
Modern PET scanners are optimized for the imaging of F-18. It is superior to
most other radionuclides in spatial resolution, half-life, availability and ease of use. In
addition, the chemistry of binding fluorine to potential microsphere materials is relatively
easier than the organometallic chemistry involved with other potential radionuclides.
Other possible candidate radionuclides for use in surrogate microspheres include Ga-68,
Cu-64, Zr-89 and Y-86.
Ga-68 is available in the form of a Ge-68/Ga-68 generator [38]. Thus, Ga-68
could be available in areas that are not serviced by a cyclotron facility. The generator is
expensive and the availability of Ga-68 is more limited than the availability of F-18.
Gallium is a metal and the binding to microspheres often involves the use of a chelator to
bind organic molecules. One group of investigators has successfully labeled
hydroxyapatite nanoparticles with Ga-68[39]. Gallium also shares chemical properties
with iron and can take the place of iron in some biological processes [40]. This could be
problematic for a gallium-labeled surrogate microsphere in the blood stream.
Copper-64 is a radionuclide that has been tested for use in surrogate microspheres
[41]. In one investigation, resin microspheres labeled with Cu-64 were injected into rats.
The binding proved to be unstable. It was found that albumin had an affinity for the Cu64 bound to the microsphere. The albumin in the blood was likely responsible for
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removing Cu-64 from the microspheres. However, other properties of Cu-64 make it
attractive for use as a surrogate radiolabel. It has a half-life of 12.7 hours. The maximum
energy of the Cu-64 positron is 0.6 MeV. This is a relatively low-energy positron which
tends to result in good spatial resolution in PET imaging. One strategy to avoid Cu-64
binding with albumin is the incorporation of naturally abundant copper into glass
microspheres. The glass is irradiated in a high flux source of neutrons to produce Cu-64.
The incorporation of the Cu-64 into the glass greatly reduces leaching. However, the
process is time consuming and requires access to special facilities for irradiation of the
microspheres.
In the investigation performed for Cu-64, testing was done with Y-86 and Zr-89
[41]. The in vivo stability of both were acceptable. The Y-86 emits a high-energy
positron (3.2 MeV) which would likely result in relatively poor spatial resolution
compared to other radionuclides used in PET. Y-86 also produces several prompt
gammas. This “dirty” energy spectrum may confound PET data acquisition and inhibit
accurate quantification. Zr-89 has a relatively low-energy positron (0.9 MeV) and no
prompt gamma rays. However, the half-life is comparatively long at 78.4 hours. Ten
half-lives is nearly 33 days. This isotope would likely not work well in the current
therapy workflow where the surrogate is administered approximately one to two weeks
prior to the administration of the Y-90 microspheres. If Zr-89 was used as a surrogate,
significant activity would be present and likely show in post-therapy bremsstrahlung
SPECT or TOF PET imaging.
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2.

Choice of Microsphere Material
Ion exchange resins were initially investigated for possible microsphere material.

There are commercial suppliers of microspheres composed of ion exchange resins.
Previous investigators have had success labeling these types of microspheres [41]. In
addition, SIR-Spheres are resin microspheres made of a proprietary resin bound to Y-90.
The investigation into ion exchange resins resulted in several concerns. One goal of this
project was to create a surrogate microsphere that would be close in size to the
therapeutic microspheres. The investigation into commercially available ion exchange
resins found that significant swelling of the resin beads could be expected. Another
potential problem was identified in regards to the ability of the resins to tightly bind
fluoride. In the Bio-Rad publication, Guide to Ion Exchange, there is a table with the title
“Relative Selectivity of Various Counterions” [42]. The table lists 23 negative ions and
their relative selectivity. The Guide states, “In general, the lower the selectivity of the
counterion the more readily it exchanges with another ion of like charge”. For the resins
used for negative ion, fluoride, F-, has the lowest selectivity in the list. This leads to the
conclusion that F- ion would not be strongly bound to the resin. The 22 other negative
ions on the selectivity list would likely replace the fluoride ion in the resin. For in vivo
applications, this could lead to removal of the ion from the resin by blood products.
Continuation of the search for a microsphere material, resulted in finding a
commercially available hydroxyapatite microsphere. These microspheres are sold by
Bio-Rad as ceramic hydroxyapatite “CHT” microspheres. The microspheres are made
from crystalline hydroxyapatite material that is compressed and sintered at high
temperatures. There are two types available, Type I and Type II. The two types are
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chemically the same. The sintering temperatures and times are different. The Bio-Rad
CHT microspheres are designed to be used as a chromatography medium in the
purification of biological molecules. The two types of CHT have different binding
properties to proteins. Subsequent research found that significant swelling of the
hydroxyapatite microspheres was unlikely.
Hydroxyapatite was identified as a promising material since it was known that [F18] NaF is used for PET skeletal imaging and hydroxyapatite is the primary mineral
component of bone. Hydroxyapatite is already widely used clinically. There are a variety
of hydroxyapatite-containing materials used as bone substitutes. These materials are
usually placed in the body as a treatment for a bone defect. Synthetic ceramic bone
substitutes are often a mixture of hydroxyapatite and tricalcium phosphate (TCP) [43].
Hydroxyapatite is the crystalline form of TCP, The ratio of the hydroxyapatite and the
TCP is adjusted based on the application. Hydroxyapatite usually provides better
mechanical strength whereas TCP enhances biodegradation. Much work has been done
to optimize bone substitutes for porosity and to mimic natural bone. Another variety of
bone substitutes are the calcium phosphate cements (CPCs) which consist of a calcium
phosphate powder. When mixed with a liquid, the resulting cement hardens into
nanocrystaline hydroxyapatite. These cements are FDA approved for repair of non-load
bearing bone defects [44].
Another potential application of hydroxyapatite is the removal of excessive
fluoride from drinking water. In a study by Fan et al., the investigators showed that
hydroxyapatite readily binds to fluorine ions in water [45]. They found that the adsorbed
fluoride molecules on hydroxyapatite plateaus at approximately 5x1013 fluoride
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molecules per gram. If the assumption is made that the fluoride is in the form of F-18,
5x1013 fluoride molecules per gram of hydroxyapatite is equivalent to 5.25 GBq per gram
or 142 mCi per gram.
The bulk density of CHT hydroxyapatite microspheres is 0.63 g/cm3[46] A
random close packing of spheres will have a packing fraction of approximately 0.63 [47].
If a packing density of 0.63 is assumed, then the density of a CHT microsphere is 1
g/cm3. The actual density of the individual microspheres is slightly greater than the
density of water. This is based on observations that in a mixture of water and CHT
microspheres, the microspheres will slowly settle to the bottom of the container. The
CHT microspheres are available in three sizes, 20 ± 2 µm, 40 ± 4 µm and 80 ± 8 µm.

A

gram of 40 µm CHT microspheres contains 3x107 microspheres. A gram of 20 µm CHT
microspheres contains 2.4 x 108 microspheres. Based on the 5.25 GBq of F-18 per gram
reported by Fan et al. it was expected that 176 Bq per microsphere for 40 µm was
achievable. A similar calculation for 20 µm results in an estimate of 22 Bq per
microsphere. This activity per microsphere is approximately the same order of
magnitude reported for other radiolabeled microspheres investigated for use as surrogates
[41].
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Figure 5: Micrographs of Type I CHT ceramic hydroxyapatite microspheres. Image on left was acquired
with American Optical Spencer 60 using 10X objective. Image on right was acquired with a Zeiss
AxioSkop MOT2 microscope at 40X magnification. Microsphere diameters consistent with manufacturer’s
claims.

As the activity per microsphere increases, the number of microspheres required
for a desired activity decreases. Reducing the number of injected microspheres reduces
the likelihood of embolic effect and the redirection of blood flow. A large amount of
activity per microsphere combined with a positron emitting radionuclide with a high
positron branching ratio results in a strong signal from a relatively small amount of
microspheres. Based on this information, it was felt that further investigation of F-18 to
CHT hydroxyapatite microspheres was worthwhile.
The unit cell of hydroxyapatite considered to have a hexagonal lattice. The unit cell is
composed of two versions of the formula units Ca5(P04)3OH [43]. The formula for
hydroxyapatite is typically written as Ca10(PO4)6(OH)2. There are two mechanisms in
which fluoride is incorporated into the apatite crystal structure [39], [48]. One
mechanism is ionic exchange via surface adsorption. This occurs at the CaOH sites [48].
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At these sites the F- is exchanged for water or OH depending on the on pH. Once the
fluoride has been adsorbed onto the surface, diffusion of fluoride into the crystal lattice
may lead to substitution of a hydroxide ion, OH-, with the F-. The fluoride is smaller than
the hydroxide ion. When the fluoride is substituted for OH- within the crystal lattice, the
result is more thermodynamically stable. The resulting material is fluorapatite,
Ca10(PO4)6F2.
There is evidence that the fluoride diffuses several nanometers into the bulk
hydroxyapatite and will reach equilibrium. The resulting fluorapatite layer may form a
barrier to further penetration of the F- into the hydroxyapatite [49]. It was expected that
the ceramic form of hydroxyapatite would present more surface area per unit mass than
the highly crystalline forms. As such the structure of the CHT would be favorable for
surface adsorption.
Sandhöfer et al., have successfully bound F-18 to hydroxyapatite crystalline
nanoparticles [39]. The synthetic material was similar to biologically produced apatite in
regards to chemical composition and morphology. The particle size of the apatite
nanoparticles was less than 30 nm. This is three orders of magnitude smaller than the
ceramic hydroxyapatite microspheres that were used in this dissertation. This group
noted that hydroxyapatite nanoparticles have a tendency to form clusters [39]. They
treated the nanoparticles with citrate to reduce the tendency to aggregate. In the case of
hydroxyapatite nanoparticles, the radiolabeling was done by mixing F-18 fluoride ions
with the nanoparticles in an aqueous solution. The initial radiopharmaceutical was [F-18]
NaF. The binding equilibrium was achieved in less than 10 minutes. The stability of
these radiolabeled hydroxyapatite nanoparticles was tested in saline and phosphate
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buffered saline. After 2 hours, the bound activity on the hydroxyapatite was greater than
95%.
The Sandhöfer group also tested the stability of the radiolabel in a rat. They
found that initially the activity localized in the lungs and then migrated to the liver. This
was attributed to particle migration due to the small particle size and not free fluoride ion.
After 90 minutes, activity in the joints of the skeleton and kidneys was not seen. The
conclusion was that the F-18 label was stable in vivo [39].
Fan et al. used highly crystalline hydroxyapatite crystals in the 200 micron range
[45]. Their equilibrium time was nearly two hours. The results from Fan and Sandhöfer,
indicate that the time required to reach labeling equilibrium seemed to decrease with
decreasing particle size. The anticipated labeling time for the CHT microspheres was
somewhere between 10 minutes and two hours.
Another investigation of F-18 binding to hydroxyapatite was published by
Jauregui-Osoro et al. [50]. In this study, three different forms of hydroxyapatite crystals
were synthesized and another form was commercially purchased. All types tested were
nanoparticles 200 nm or less in size. This is two orders of magnitude smaller than the
CHT microspheres planned for use this study. Jauregui-Osoro et al. injected F-18
radiolabeled hydroxyapatite into the tail veins of mice. The radiolabel of the
nanoparticles that remained in the lungs was stable. There was evidence that
nanoparticles that migrated to the liver and spleen were taken up by phagocytic cells of
the reticuloendothelial system. The size of these macrophages appear to be
approximately 10 µm in diameter [50]. These nanoparticles then gradually released F-18
which then collected in the skeleton. It was expected that the CHT microspheres would
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not undergo uptake by phagocytic cells due to the size of the microspheres. The CHT
microspheres are 20 µm or 40 µm in diameter. A study by Champion et al. found that
particles with diameters 2 µm to 3 µm of had maximum particle uptake by macrophages
[51].
Das et al. manufactured hydroxyapatite microspheres in the 20 to 60 µm size
range [52]. They radiolabeled their microspheres with holmium-166. They were able to
image the Ho-166 labeled microspheres with a gamma camera using the 81 keV photons.
They mention that hydroxyapatite is biodegradable and is eliminated in 6 weeks. They
examined parameters that could affect radiolabeling such as particle concentration, pH,
temperature, and incubation time.

S.

Research Goals
A positron-emitting surrogate particle for the Y-90 microspheres was developed

such that the new surrogate particle was stable in vivo and had a size distribution closer
to Y-90 microspheres than Tc-99m MAA. The new surrogate particle was designed for
imaging using PET which is superior to SPECT for quantitative imaging. Pre-treatment
PET data was used with a Monte Carlo simulation program to perform accurate pretreatment dosimetry. Calculated Y-90 doses were confirmed with actual measurements
using beta dosimetry. The research goal in this dissertation can be divided into two aims,
the development of a positron emitting microsphere and the demonstration of dosimetry
that utilizes PET imaging.
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1.

Aim 1: Positron Microsphere Development
A microsphere was labeled with a positron-emitting radionuclide to create a

surrogate for Y-90 microspheres. The size of the surrogate was matched to the size of the
Y-90 microspheres. The surrogate microsphere and radiolabel were selected such that the
radiolabeling process was relatively simple. The microsphere and positron-emitting label
were selected such that the materials are easy to acquire and non-toxic.
In vitro testing of the radiolabeled microspheres was performed in the presence of
blood products to assess the binding of the radiolabel to the microsphere. Unlike Tc-99m
MAA, the degradation of the surrogate particle did not become significant in the period
that imaging occurs.
A relatively small amount of PET microspheres were needed to provide enough
positrons to produce useful activity distributions with PET. Keeping the number of
microspheres to a minimum help avoid embolic effects such as stasis and reflux.
In vivo testing of the surrogate microspheres involved administration into an
animal. The radiolabel was sufficiently bound such that activity was not removed from
the surrogate microsphere by blood flow or other physiologic processes. Whole body
PET imaging of the animal was used to assess removal of the positron emitting radiolabel
from the microspheres. This was a preliminary test required before human use is
considered.
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2.

Aim 2: Dosimetry
The goal was to demonstrate that PET imaging of the surrogate microsphere

distribution can be used to calculate the absorbed dose distribution due to Y-90
microspheres
A phantom containing the surrogate radionuclide was imaged with PET. The
PET data was used to create a voxelized source in a Monte Carlo simulation.
The activity of Y-90 during the PET acquisition can be calculated based on the
initial activities of the surrogate radionuclide and Y-90. The majority of absorbed dose to
a region of interest is due to the beta electrons from Y-90. The absorbed dose in a region
of interest was calculated with the Monte Carlo simulation. The actual dose to the same
region of interest was measured with beta dosimetry. The beta dosimetry was performed
with radiochromic film and a calibrated source of electrons

II.

Surrogate Microsphere Development

A.

Radiolabeling

1.

Introduction
The purpose of these experiments was to investigate the process of radiolabeling

hydroxyapatite microspheres with fluorine-18. A variety of labeling conditions were
investigated such as initial activity concentration, activity per mass, pH, and form of
hydroxyapatite. These experiments were designed as a broad parametric survey.
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Other investigators have demonstrated significant adsorption of F-18 on to
hydroxyapatite[39], [45], [50]. For instance, calculations indicate that Fan et al. were
able to bind an estimated 5x1013 molecules of fluoride per gram of hydroxyapatite. This
is equivalent to 142 mCi of F-18 per gram of hydroxyapatite. These experiments were to
determine if it was possible to bind mCi amounts of F-18 to milligrams of ceramic
hydroxyapatite microspheres. The binding of F-18 to the microspheres was expected to
similar to follow a trend similar to that shown in Fan et al., Figure 1 [45]. In this figure,
the adsorption increases rapidly and the percent adsorption reaches 80% within 50
minutes. The adsorption continues to increase and is nearly 100% at 150 minutes past the
time at which the F-18 was added to the hydroxyapatite.
A method used to monitor the adsorption of the F-18 fluoride ion onto the
hydroxyapatite was to sample the liquid supernatant surrounding the microspheres. As
the F-18 binds to the microspheres, the amount of F-18 in the supernatant will decrease.
The rate of F-18 removal from the supernatant follows the rate of adsorption on to the
hydroxyapatite microspheres.

2.

Methods
Radiolabeling was performed with F-18 sodium fluoride, [F-18] NaF, supplied as

a unit dose by PETNET Solutions Inc., a subsidiary of Siemens Medical Solutions USA,
Inc. The F-18 sodium fluoride provided by PETNET is their “injectable” form and is
FDA approved for injection into humans. The PETNET F-18 sodium fluoride for
injections is a clear, colorless, pyrogen-free, preservative-free, isotonic aqueous solution
of 0.9% sodium chloride. The solution activity is between 10 mCi to 200 mCi per mL.
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The solution pH is between 4.5 and 8 [53]. The [F-18] NaF unit dose was produced at a
PETNET cyclotron facility and delivered the day of the experiment.

Figure 6: Schematic of dose calibrator with cut-away view of ionization chamber with well geometry.

The dose calibrator used during the radiolabeling experiments was a Capintec
CRC-7R, serial number 70723. A dose calibrator is an ionization chamber with a welltype geometry. Commercial dose calibrators are able to accurately measure the activity
of a radioactive sample over six or more orders of magnitude. The activity range that
was measured in the dose calibrator during the radiolabeling experiments was
approximately 0.01 µCi to 20 mCi.
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Figure 7: Shown is the dose calibrator used in these experiments. The readout module has the LED digits,
range buttons and potentiometers for adjustment. The ionization chamber is the cylinder on the right side
of photo.
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Figure 8: Calibration source for F-18 in a dose calibrator dipper. The dipper is partially in the well of the
dose calibrator ionization chamber. The source is NIST-traceable with a known activity of Ge-68/Ga-68.
Gallium-68 is a positron emitter. The Ga-68 activity is converted into NIST-traceable activity for F-18.

Prior to the labeling experiments, the dose calibrator was calibrated for F-18 using
a Ge-68/Ga-68 calibration source. The calibration source is a model BM06S Positron
Reference Standard manufactured by RadQual LLC. The source contains Ge-68 and Ga68 uniformly distributed in 3 milliliters of colored epoxy. The Ge-68 decays to Ga-68.
The daughter nuclide, Ga-68, is in secular equilibrium with the parent nuclide, Ge-68.
The value of the Ge-68 half-life used in the source certificate was 270.8 days. A copy of
the source certificate is in Appendix A. The daughter nuclide, Ga-68, is a positron emitter
with a half-life of 67.7 minutes [35].

The value on the source certificate for the
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Gallium-68 percent abundance for 511 keV photons is 178.2%. The source is NIST
traceable with a declared uncertainty of 1.15% with a 95% confidence level. The vendor
provides a “Decay Reference Calendar” in which the Ga-68 activity and F-18 activity on
a given date are listed. The percent abundance of F-18 for 511 keV photons is 193.5%
[35]. The Ga-68 activity is scaled by the percent abundances to produce an equivalent F18 activity. The apparent F-18 activity is used to calibrate the dose calibrator for F-18.
The process to check a dose calibrator for accuracy of fluorine-18 measurements
was relatively straightforward. The calibration source was placed into the same geometry
used to measure F-18 samples and the F-18 channel was selected. The displayed activity
was compared to the expected F-18 activity. The calibration potentiometer was adjusted
until the displayed activity matched the expected activity for the F-18 channel and Ge68/Ga-68 source. In this instance, the calibration number that resulted in the best
agreement was 488. This calibration number was used in all subsequent radiolabeling
experiments.
The expected activity was calculated by extending the Decay Reference Calendar
beyond the vendor published values. This was done by decay-correcting the activity
using the 270.8 day half-life of Ge-68.

48

Figure 9: PerkinElmer "Wizard2" model 2480 automatic gamma counter.

Many of the samples measured in the dose calibrator were also measured in an
automated NaI(Tl) detector system. The system was a Wizard2 gamma counter model
2480 manufactured by PerkinElmer, serial number DG04129132. The system was
calibrated for F-18 measurements using a small amount of F-18 per instructions provided
by the vendor. In the first two radiolabeling experimental runs, 25 µL aliquots were
used. During the remaining radiolabeling experiments, the aliquot size was 50 µL. At
the conclusion of each labeling experimental run, all of the aliquot samples were placed
into a rack. The Wizard2 sample counter was used to perform automated reading of
counts from the samples.
An effort was made to keep variations in the dose calibrator readings due to
geometric effects and the effects of containers to a minimum. During any given
experimental run, there were three types of containers used. The 3 mL syringe that
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PETNET used for the unit dose, the 15 mL polypropylene centrifuge containers, and the
PerkinElmer vials used in the PerkinElmer Wizard2 automated sample counting system.

Figure 10: Shown is 3 mL syringe with needle used by PETNET to deliver F-18 sodium fluoride unit dose.

Figure 11: Two different models of 15 mL polypropylene centrifuge tubes used in these radiolabeling
experiments.
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Figure 12: PerkinElmer sample vial (left). Vials in rack ready for counting in Wizard2 counting system.

Geometric effects with the PerkinElmer vials were not significant. The aliquots
were always the same volume. In any given experiment run, the amount of liquid in the
PerkinElmer Wizard2 containers remained constant. Usually this was 50 mL. Care was
taken to ensure that the PerkinElmer vials were measured in the same location in the dose
calibrator.
The volume of the unit dose delivered by PETNET in the 3 mL syringe varied
between 0.5 mL and 2.5 mL. The volume was adjusted by pulling liquid into the syringe.
The type of liquid used to adjust depended on the particular experiment. In early
experiment, de-ionized water was used. In later experiments, phosphate buffered saline
(PBS) was often used. The final volume of the adjusted unit dose was between 2.5 and
3.1 mL. Once the desired volume was achieved, the activity in the syringe was measured
in the dose calibrator. A single measurement was recorded for the final volume of liquid
in the syringe. The variation in the dose calibrator measurements due to geometric
effects of different dose volumes is plotted in Figure 13. The percent difference in the
2.5 to 3.1 mL range is approximately 0.5%.
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Variation in Dose Calibrator Readings Due To
Geometric Effects in 3 mL Syringe
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Figure 13: Variation in dose calibrator readings due to geometric variation in 3 mL syringe. Data has been
normalized to a volume of 0.5 mL.

In any given experiment run, the amount of liquid in the centrifuge tubes could
vary. Geometric effects in the centrifuge tube were measured. A 0.6 mL sample
containing F-18 was placed in a centrifuge tube and the activity was measured and time
recorded. An autopipette was used to add 1 mL of de-ionized water. The activity was
measured and the time recorded. The activity was increased in 1 mL increments to a
volume of 13.6 mL. With the data normalized to 0.6 mL, the maximum deviation of
1.81% occurred at 12.6 mL. The results are plotted in Figure 14. In most instances, the
volume change over an entire experiment run would vary from approximately 0.5 mL to
5 mL. This would likely result in an approximate error of +/- 0.5% from geometric
effects.
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Variation in Dose Calibrator Readings Due To
Geometric Effects in Centrifuge Tube
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Figure 14: Variation in dose calibrator readings with different volumes of liquid in centrifuge tube. Data
was normalized to 0.6 mL reading.

There may have been effects going from one container type to another. The
activity variation between the 3 mL syringe and the centrifuge tube was measured. An
activity of 1.618 mCi in 0.5 mL was measured in the 3 mL syringe. This was injected
into a centrifuge tube. The residual activity in the syringe and the activity in the
centrifuge tube were measured and corrected for decay. An activity discrepancy of
0.47% was measured between the 3 mL syringe and the centrifuge tube.
The linearity when switching between activity scales on the dose calibrator was
checked. A source was measured on the 20 mCi scale and then on the 2000 µCi scale. A
difference of 7.45% was measured. The round-off error on the 20 mCi scale contributes
to this difference. On the 20 mCi scale, only two digits to the right of the decimal are
displayed, whereas more are displayed on the 2000 µCi scale. A source was also
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measured with the dose calibrator on the 2000 µCi scale and then the 200 µCi scale. A
difference of 1.1 % was found for the measured activity of the same source. The test was
repeated for the 200 µCi scale and 20 µCi scale. A source was measured with the dose
calibrator on the 200 µCi scale and then the 20 µCi scale. A difference of 0.03 % was
found for the measured activity of the same source.
In many measurements and subsequent calculations, the dose calibrator accuracy
was not critical since the final calculation was a ratio of the activities measured. Thus,
relative activity was important, not the absolute activity. In general, for the dose
calibrator measurements, the estimated uncertainty was low. Another method to estimate
the uncertainty of the dose calibrator measurements was to compare the data to the
Wizard2 data. The count data from the Wizard2 enabled calculation of uncertainty based
on counting statistics.
The hydroxyapatite was in the form of ceramic microspheres purchased from BioRad Laboratories, Inc. and marketed as CHT ceramic hydroxyapatite particles. The
microspheres are available in 20 µm, 40 µm and 80 µm diameters. The microspheres
used in these radiolabeling experiments were 20 um in diameter. The volume of a single
microsphere is 4.2×10-9 cubic cm. The volume of 1 million microspheres is 4.2×10-3
cubic cm. The density in a packed bed of CHT 20 µm microspheres is 0.63 g/mL. The
packing density for a packed bed of spheres was assumed to be 63%. The density of the
hydroxyapatite microsphere is approximately 1 g/mL. Thus, the mass of 1 million of the
20 um-diameter microspheres is 4.2 mg. The number of microspheres per unit mass is
2.4×105 per mg. The CHT microspheres are available in two types, Type I and Type II.
According to the vendor’s literature, Type I has a smaller pore diameter (600-800
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angstroms) compared to Type II (800-1000 angstroms) [54]. The lot number for Type I
was S401021. The lot number for Type II was S700928. Both types of CHT
microspheres were used.
Prior to labeling, the dry hydroxyapatite was measured with an analytical balance.
The balance was a Mettler-Toledo AB-S/FACT, serial number 1128042661. This
analytical balance has a 0.1 mg resolution. The most commonly used containers for
mixing hydroxyapatite and F-18 sodium fluoride were 15 mL polypropylene centrifuge
tubes. To begin weighing the microspheres, a 15 mL centrifuge tube was placed on the
analytical balance. The balance reading was set to zero milligrams. A small amount of
hydroxyapatite was then added to the centrifuge tube and the mass of the hydroxyapatite
was measured. Material was added until the desired mass of hydroxyapatite was reached.
In the first experiment, the mass of hydroxyapatite was 102.6 mg. Subsequent
experiments, the mass of hydroxyapatite was much less. The range of masses for
subsequent radiolabeling experiments was 4.0 mg to 10.5 mg.
The typical volume of the unit dose delivered by PETNET was 0.5 mL to 2 mL of
F-18 sodium fluoride in a 3 mL syringe. Usually the volume was adjusted by adding
saline, deionized water or phosphate buffered saline (PBS). In one run, sodium citrate
dehydrate (EMD Millipore, Inc.) was used to prepare 500 millimolar solution of sodium
citrate buffer. The goal was to see if the citrate had any effect on adsorption or
disassociation of the F-18.
Once the desired volume was achieved, the activity of the unit dose of sodium
fluoride was measured in the dose calibrator. The volume of the unit dose was recorded.
When the desired activity and volume was reached, a small volume of the [F-18] NaF
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liquid was removed for measurement of the pH. A second sample of the liquid was
removed. This sample was usually a fixed volume of 50 µL removed with an autopipette.
The time that this aliquot was removed from the liquid was recorded. This sample was
usually designated “aliquot 1”. The activity concentration in aliquot 1 (µCi/mL) was the
same as the activity concentration of the bulk [F-18] NaF liquid. The rate of radioactive
decay in the [F-18] NaF liquid and in aliquot 1 was always the same. For any subsequent
times, the activity concentration of aliquot 1 would always be same as the activity
concentration of the [F-18] NaF unit dose prior to the addition of the unit dose to the
hydroxyapatite microspheres. The activity concentration of the bulk [F-18] NaF liquid
prior to the addition of hydroxyapatite was an important measurement for adsorption rate
calculations.
Prior to adding the F-18 sodium fluoride to the hydroxyapatite, a small sample of
the liquid was removed. This sample was used for measurement of the pH. The pH the
F-18 sodium fluoride was measured using BAKER-pHIX pH test strips. The test strips
are sensitive to a specific pH range. Type 4394-01 was used to measure in the pH range
3.6 to 6.1. Type 4396-01 was used to measure a pH range of 6.0 to 7.7. Type 4398-01
was used to measure pH in the 7.5 to 9.5 range. At the beginning of this study, the
accuracy of the strips was checked with pH calibration solutions of known pH.
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Figure 15: Test strips for pH measurement

The pH of the unit dose delivered by PETNET was usually found to be in the
range of 5.6 to 6.1. In the early radiolabeling experiments, the [F-18] NaF solution used
to radiolabel the hydroxyapatite was also in the acidic range of 5.6 to 6.1. The
radiolabeling results produced with these solutions were very good. However, there was
concern that the slightly acidic solution was increasing the rate of disassociation during
the washing phase of the experiment. CHT hydroxyapatite is designed for use in protein
purification. A “Golden Rule” stated by Bio-Rad in bulletin 6932 is to keep the pH> 6.5
throughout the purification process. In light of the recommendation from Bio-Rad, the
pH of subsequent [F-18] NaF solutions were adjusted with PBS buffer to be greater than
a pH of 6.5.
After the removal of the first aliquot and pH sample, the [F-18] NaF solution was
added to the CHT hydroxyapatite microspheres. The F-18 sodium fluoride was injected

57

into the centrifuge tube containing the hydroxyapatite microspheres. The injection time
was recorded. After injection, the residual activity in the 3mL syringe was measured and
the time recorded. The material was mixed by shaking the vial until the particles were
suspended in the fluid. In early trials, the mixture was placed on a rocker for one minute.
It was found that the binding of F-18 to the microspheres was very rapid. After the first
few experimental runs, the rocking step was skipped in order to get more aliquots of the
supernatant. In these instances, the mixture was shaken by hand until the hydroxyapatite
microspheres were in suspension and then the tube was placed in the centrifuge.
It was found that 2500 RPM for 1 minute was sufficient to force the
microspheres into a pellet. The centrifuge was not absolutely necessary but did speed the
separation of the microspheres from the supernatant. The uptake was usually so rapid
that to gather multiple data points during the adsorption process, the centrifuge was
needed to rapidly separate the mixture. After the hydroxyapatite was centrifuged into a
pellet, a 50 µL aliquot of the supernatant was withdrawn. The time that the aliquot was
removed from the supernatant was recorded. The aliquot of supernatant was measured in
the dose calibrator. The time and activity of the aliquot were recorded. The aliquot was
set aside for later measurement in the automated sample counter. The sodium fluoride
and hydroxyapatite mixture was then shaken until the microsphere pellet was dissolved
and the microspheres were resuspended in the fluid. The mixture was then centrifuged
again. The cycle of shaking, centrifuging, aliquot removal, and activity measurement
continued until the activity of the aliquots appeared to plateau.
To maintain the same measurement geometry, care was taken to ensure that all
aliquots were measured at the same position within the dose calibrator. All aliquots were
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measured in the dose calibrator, labeled and set aside. Towards the end of the experiment
run, the aliquots were placed in racks and counted with the Wizard2 automated sample
counter.
When an aliquot is removed from the supernatant, the activity concentration
ceases to be influenced by adsorption on the hydroxyapatite. After removal, the only
factor influencing the activity concentration is radioactive decay. The time of removal
was recorded for each aliquot. Thus, it was possible to correct the measured activity in
an aliquot for radioactive decay. In this way, the activity concentration of the
supernatant was sampled over time.
A concern was the possible binding of F-18 to the polypropylene centrifuge tubes.
This was investigated during the labeling experiment performed on 9/12/2017. The
hydroxyapatite and sodium fluoride had been mixed in a polypropylene centrifuge tube.
After the radiolabeling phase of the experiment was complete, the centrifuge tube
containing the hydroxyapatite and remaining supernatant was measured in the dose
calibrator. The measured activity was 7.60 mCi. The mixture was then transferred to a
glass tube. The polypropylene centrifuge tube was rinsed with 6 mL of de-ionized water.
The rinse water was added to the hydroxyapatite mixture in the glass tube. After rinsing,
the remaining activity of the centrifuge tube was measured with the dose calibrator. The
decay-corrected activity of the centrifuge tube was 45.3 µCi. This activity is 0.6% of the
mixture activity.

The glass tube containing the hydroxyapatite, supernatant and rinse

water was measured. The decay corrected activity was 7.53 mCi. There was a 25 µCi
discrepancy in the activity accounting. This represents 0.3% of the initial activity. The
slight difference in activity measurements was likely due to difference in volumes and
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container materials affecting the dose calibrator measurements. The initial measurement
was done with the mixture in polypropylene with a liquid volume of 0.8 mL. The second
measurement was done with the mixture in glass with a volume of 6.8 mL. The
conclusion was that the binding of F-18 to the polypropylene centrifuge tubes was not
significant.
Another potential source of error was the possibility that during removal of the
aliquots, a small amounts of microspheres were being collected by the pipet. This was
especially a concern when the volume of the supernatant was low and the pipet tip was
close to the hydroxyapatite pellet. The method used to check for the inadvertent pick up
of microspheres was to take two aliquots of identical volume. One was taken from the
top of the supernatant, far from the pellet. The other aliquot was taken from the
remaining supernatant near the hydroxyapatite pellet. If microspheres were still in
suspension or were being removed from the pellet due to agitation, then the microsphere
concentration would likely be greater in the aliquot taken near the pellet. If this were the
case, the second aliquot would likely have a greater activity than the first aliquot. This
method was used in several instances. As an example, on 9-12-2017 after the
radiolabeling phase of the experiment was complete, the mixture was centrifuged at 4000
rpm for 3 minutes. Afterwards, 1 mL of supernatant was removed and labeled “super 1”.
Another 1 mL of supernatant was removed and labeled “super 2”. The second
supernatant sample was drawn much closer to the hydroxyapatite pellet. If microspheres
were being drawn into the pipet, the second sample was expected to have a greater
activity than the first sample. The decay-corrected activities of “super 1” was 17.9 µCi
and 17.6 µCi for “super 2”. The second activity was actually slightly less than the first.
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This method is likely to be sensitive to a difference of a few microcuries. In this
instance, a 1 µCi amount of microspheres represents 0.0013% of the total activity bound
to the microspheres.
Below is a summary of the uncertainties that may have contributed to
measurement error during these experiments. Each uncertainty listed in the table, may or
may not have been applicable, depending on the specific circumstances of the
experiment.

Table 1: Sources of measurement uncertainties

Measurement
Dose calibrator accuracy
Dose calibrator geometric variation in
centrifuge tube
Resolution of dose calibrator
Linearity between activity range 20 mCi
and 2000 µCi scale.
Linearity between activity range 2000 µCi
and 200 µCi scale
Linearity between activity range 200 µCi
and 20 µCi scale
Resolution of analytic balance
3.

Uncertainty
1.15%
0.5%
0.01 µCi
7.45%
1.1%
0.03%
0.1 mg

Results
Eight radiolabeling runs were performed. For these experiments, the fraction of

initial activity in the supernatant over time is shown in Figure 16. The activities shown in
Figure 16 were measured in the Capintec CRC-7 dose calibrator. All activities were
corrected for radioactive decay. The units along the horizontal axis are minutes since the
[F-18] NaF was added to the hydroxyapatite microspheres. In Figure 16, the time when
the F-18 sodium fluoride was added to the hydroxyapatite was designated as time = 0.
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As the F-18 was binding to the hydroxyapatite, the activity concentration of the
supernatant was decreasing. Overall the binding was rapid. In most instances 90% of
the activity was removed from the supernatant within the first 10 minutes.
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Figure 16: Fraction of initial activity in supernatant plotted at the time points when the aliquots were
removed from the supernatant. All activities have been corrected for radioactive decay. The activity
measurements were performed with the dose calibrator.
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The results from the 10-12-2017 run with Type II microspheres show that the
binding was much slower than in other experimental runs. It does appear that given
enough time, the activity in the supernatant would have plateaued in the sub-five percent
range. The cause of this slow binding is unknown. It is unlikely that the unit dose was
contaminated. The unit dose from PETNET was split. The radiolabeling done with the
first half-dose had results similar to other results. These results are plotted as “10-122017 Type I” in Figure 16. After examination, the current belief is that the wrong
concentration of PBS was used in the 10-12-2017 Type II radiolabeling experiment. The
supply of PBS used for radiolabeling and washing was occasionally resupplied from a
larger bottle of PBS (Gibco 1x). There was a bottle of Gibco 10x concentrated PBS in
the lab at the time. The labels look very similar. It is possible that the 10x strength was
used inadvertently. Another possibility investigated was detector error. For all
experiment runs, the aliquots were measured in the dose calibrator and then later
measured in the Wizard2 sample counter.
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Figure 17: Fraction of initial activity in supernatant as measured by Capintec dose calibrator and Wizard 2
sample counter. The largest uncertainty due to counting statistics for the Wizard2 data was 0.158%.

Figure 17 is a plot of the data from the 10-12-2017 run with Type II microspheres.
Plotted in this figure are the results from the dose calibrator and the Wizard2 sample
counter. The data from the Wizard2 sample counter closely matches the measurements
from the dose calibrator. The sample counter results are in the form of number of counts
from a sample. Counting statistics were applied to this data. For the aliquot that was
initially removed, prior to the addition to hydroxyapatite, the count rate was 4,011,842
cpm. The rate was corrected for dead time and background counts were subtracted. The
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next aliquot was removed from the supernatant 4.75 minutes after the addition of the [F18 NaF liquid to the hydroxyapatite. The count rate for this aliquot measured 1,711,411
cpm. This was also corrected for dead time and background counts were subtracted.
Subsequent aliquot count rates were decay-corrected to the beginning of the assay. The
ratio of the two count rates is 0.4266. Based on counting statistics associated uncertainty
for the ratio of the two count rates is 0.094%. The largest uncertainty due to counting
statistics for the six measurements obtained with the sample counter was 0.158% for the
last aliquot removed from the supernatant.
In general, statistical uncertainty for the Wizard2 data was low and closely
matched the dose calibrator measurements. The following graphs are plots of the fraction
of initial activity in the supernatant as calculated using the CRC-7 dose calibrator data
and the data from the Wizard2 gamma counter. The gamma counter data was in the form
of counts. Standard methods of error propagation were applied to calculate the
uncertainty based on the counting statistics.

65

Fraction of Initial Activity in Supernatant
Experiment Run 8-31-2017 Type I

Fraction of Initial Activity in Supernatant

1.2
1

Dose Calibrator
Measurements
Gamma Counter
Measurements

0.8
0.6
0.4
0.2

0
0

5

10

15

20

25

30

Minutes After Addition of F-18 NaF to Hydroxyapatite

Figure 18: Fraction of initial activity based on dose calibrator measurements and gamma counter
measurements. The largest uncertainty due to counting statistics was 0.534%
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Figure 19: Fraction of initial activity based on dose calibrator measurements and gamma counter
measurements. The largest uncertainty due to counting statistics was 0.561%
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Figure 20: Run 9-12-2017. The largest uncertainty due to counting statistics was 0.242%
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Figure 21: Run 9-21-2017. The largest uncertainty due to counting statistics was 0.552%
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Fraction of Initial Activity in Supernatant
Experiment Run 9-21-2017 Type I Citrated
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Figure 22: Run 9-21-2017 Citrated. The largest uncertainty due to counting statistics was 0.334%
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Figure 23: Run 10-12-2017 with Type I microspheres. The largest uncertainty due to counting statistics
was 0.483%
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The following table lists the parameters and results of each radiolabeling experimental
run.

Table 2: Results of Radiolabeling Experiments
Date of
Experiment Run

8/29/17

8/31/17

9/7/17

9/12/17

9/21/17

9/21/17

10/12/17

10/12/17

2/2/18

Microsphere Type

I

I

I

II

I

I

I

II

II

Initial microsphere
preparation

none

none

none

none

none

citrate

none

none

none

Material to adjust
unit dose

D.I.
H20
or
0.9%
saline

D.I.
H20
or
0.9%
saline

D.I.
H 20
or
0.9%
saline

D.I.
H20
or
0.9%
saline

PBS

PBS

PBS

PBS

PBS

pH at time of NaF +
hydroxyapatite

5.56.0

5.66.1

5.66.1

5.66.1

7.07.3

6.77.0

6.77.0

6.77.0

7.4

Initial mass of
hydroxyapatite (mg)

102.6

7.4

9.4

7.8

4.0

10.5

3.5

2.7

6.9

Initial activity (mCi)

6.54

12.15

10.65

9.42

4.38

2.03

6.15

2.23

4.71

Initial volume of
unit dose (mL)

3.0

2.8

3.1

2.8

2.5

2.5

2.4

3.0

8.0

Initial concentration
of F-18 NaF
(mCi/mL)

2.18

4.34

3.44

3.36

1.75

0.50

2.56

0.74

0.59

Initial activity per
mass (mCi/mg)

0.06

1.64

1.13

1.21

1.10

0.19

1.76

0.83

0.68

Minimum
radiolabeling
efficiency %

99.8

99.5

99.7

99.2

99.4

97.0

98.8

88.4

96.1

The microspheres were either Type I or Type II. In most radiolabeling
experiments Type I was used. There was little difference in radiolabeling performance.
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The outlier data set from 10/12/17 occurred with Type II microspheres. Whether the
microsphere type was a factor in the slow rate of adsorption is not known.
Data regarding the pH of the initial solution was acquired. In early radiolabeling
experiments, the unit dose volume was adjusted with de-ionized water or 0.9% NaCl
saline. This pH was measured with test strips and was in the range 5.5 to 6.1. The effect
of pH on the labeling rate and labeling efficiency was a question of concern. In addition,
there was suspicion that the rate of disassociation of the radiolabel was being influenced
by the pH during labeling. Further investigation found that the manufacturer of the
hydroxyapatite, Bio-Rad, recommended a pH greater than 6.5. For subsequent
radiolabeling runs, the unit dose volume was adjusted with phosphate buffered saline
(PBS) which had a pH of 7.4. Using this to adjust the [F-18] NaF liquid volume
increased the pH to greater than 6.5.
Up to the experiment on 2/2/2018, previous pH measurements were done with the
BAKER-pHIX pH test strips. The experiment on 2/2/2018 was an attempt to reproduce
some of the conditions present during the anomalous run on 10/12/17 with Type II. To
do this, the initial activity concentration of the 2/2/2018 run was purposely made low,
0.59 mCi/mL and the pH was relatively high at 7.4. The pH for the 2/2/2018 was
measured with an electronic pH meter. The meter was a Beckman model 360 serial
number 3016. The meter calibration was performed with calibration solutions of known
pH. The advantage of using pH strips is that the amount of liquid required is small. The
pH meter requires enough liquid to cover the probe active area. The volume required to
cover the probe was approximately 1 mL. During the 2/2/2018 experiment run, 1 mL
aliquots were withdrawn instead of the 50 µL aliquots typically used. Thus, the initial
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volume of the [F-18] NaF liquid had to be much larger than in previous experimental
runs. As can be seen in Figure 24, the experiment run on 2/2/18 did not reproduce the
slow adsorption rate seen in the 10-12-17 experimental run with Type II.
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Figure 24: Fraction of initial activity in supernatant. Both experimental runs were performed with Type II
CHT hydroxyapatite microspheres.

The pH of the 2/2/2018 as measured with the electronic pH meter is plotted in
Figure 25. The pH of the 2/2/2018 run appears to remain fairly constant during the
reaction time and does not vary from the initial pH. This is likely due to the large amount
of PBS buffer used in the initial solution.
For the 10/12/17 Type II run, the pH of the initial solution was measured. The
initial solution consisted of 0.7 mL of the original unit dose from PETNET. The volume
was adjusted to 3 mL with PBS. The pH of this solution measured 6.7 to 7.0 with the pH
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strips. This pH was within the typical pH range seen during other experimental runs.
These results indicate that pH was not the factor in producing the anomalous results seen
on the 10-12-2017 Type II run.

pH of Supernatant Aliquots
Experiment Run 2-2-2018 Type II
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Figure 25: pH of aliquots removed from supernatant during experiment run 2/2/2018.

In these radiolabeling experiments, a value of primary interest was the labeling
efficiency. The simple radiolabeling equation can be written as the following:

𝐿𝑎𝑏𝑒𝑙𝑖𝑛𝑔 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 %
= 100 𝑥

𝑚𝑖𝑐𝑟𝑜𝑠𝑝ℎ𝑒𝑟𝑒 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦
(𝑚𝑖𝑐𝑟𝑜𝑠𝑝ℎ𝑒𝑟𝑒 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 + 𝑠𝑢𝑝𝑒𝑟𝑛𝑎𝑡𝑎𝑛𝑡 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦)
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(2.1)

When the activity removed in the aliquots is considered, the activity accounting
becomes slightly more complex. The simple labeling efficiency equation assumes that all
of the activity introduced into the mixture remains in the mixture throughout the entire
labeling process. However, in these experiments, the decay-corrected activity of the
mixture at the end of the labeling process was not the same activity that was initially
added to the hydroxyapatite microspheres. Small amounts of activity were removed with
each aliquot.

If each aliquot had been returned to the reacting mixture in the centrifuge

tube, then the simple labeling efficiency equation could be used. However, this was not
done.
The aliquots were not added back to the hydroxyapatite-sodium fluoride mixture
for several reasons. During the handling of small amounts (50 µL) of liquid, including
measurement in a dose calibrator, there would be a high probability of significant residual
activity in the pipet tips and PerkinElmer vials. In addition, the experiment plan included
measurement of the 50 µL aliquots in the Wizard2 gamma counter. The aliquot activity
was measured with two completely different radiation detection systems. This
redundancy in data acquisition proved to be useful.
Each aliquot contained an amount of radioactivity that was permanently removed
from the system. To account for the activity removed in each aliquot, a modified version
of the labeling efficiency equation was used. In this metric, it is assumed that the activity
that was removed with the aliquots would not have adsorbed on to the hydroxyapatite
microspheres had it remained in the mixture. This is an unrealistic assumption, however
is does put a lower boundary on the labeling efficiency. This metric is the minimum
labeling efficiency:
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𝑀𝑖𝑛𝑖𝑚𝑢𝑚 𝐿𝑎𝑏𝑒𝑙𝑖𝑛𝑔 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 %
= 100 𝑥

𝑚𝑖𝑐𝑟𝑜𝑠𝑝ℎ𝑒𝑟𝑒 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦
(2.2)
(𝑚𝑖𝑐𝑟𝑜𝑠𝑝ℎ𝑒𝑟𝑒 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 + 𝑠𝑢𝑝𝑒𝑟𝑛𝑎𝑡𝑎𝑛𝑡 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 + ∑ 𝑎𝑙𝑖𝑞𝑢𝑜𝑡 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦)

The summation term in the denominator is the sum of the aliquot decay-corrected
activity permanently removed from the reacting mixture. The supernatant term is the
activity of the remaining supernatant remaining in the reaction vial with the
hydroxyapatite. The labeling efficiency is greater than or equal to the minimum labeling
efficiency.
The minimum labeling efficiency for all experiment runs was quite high. All runs
except the 10-12-17 Type II run, had minimum labeling efficiencies greater than 96%.
To perhaps put this labeling efficiency into perspective, most clinical
radiopharmaceuticals are prepared at a commercial radiopharmacy from a “kit” and a
radioactive solution. The kit contains the pharmaceutical precursor and the radioactive
component is added to the kit to radiolabel the pharmaceutical. The preparation of most
kits involve the addition of Tc-99m pertechnetate. After the kit is prepared, tests are
performed to measure the radiochemical purity which is the amount of radiolabeled
product in the desired form. Most kits for commercial radiopharmaceuticals consider a
radiochemical purity of 90% or greater to be acceptable for administration to patients.
The small volume of the aliquots (50 µL) was a compromise. Each aliquot had to
contain enough activity to get a reliable measurement in the dose calibrator. However,
the volume needed to be kept small so as to not significantly perturb the reacting system.
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The sum of the decay-corrected aliquot activity as a percent of the initial activity was
kept low. In most instances the sum of the aliquot activity was less than 1% of the initial
activity. In the 2/2/2018 experiment run, due to the relatively large 1 mL aliquots, the
sum of the aliquot activity was 3.7% of the initial activity.
Another parameter of interest was the amount of F-18 that could be adsorbed onto
the hydroxyapatite microspheres. As previously mentioned, Fan et al. were able to bind
142 mCi of F-18 per gram of crystalline hydroxyapatite. The amount of activity per gram
is approximately 176 Bq per microsphere for 40 µm diameter microspheres. For all of
the radiolabeling experiments, the 20 µm diameter microspheres were used. Per unit
mass, there are 8 times as many 20 µm microspheres than 40 µm microspheres. Thus for
a given activity per mass, 176 Bq/microsphere for 40 µm microspheres is equivalent to
approximately 22 Bq/microsphere for 20 µm microspheres. This value was the initial
“target” value for activity per microsphere. It was hoped that ceramic apatite would
provide more surface area and active sites. It was anticipated that the amount of activity
would be greater than what would be expected from crystalline hydroxyapatite.
These experiments have shown that it is possible to consistently radiolabel
ceramic hydroxyapatite microspheres in the approximately 100 Bq/microsphere range for
20 µm microspheres. This is five times the “target” activity per microsphere. In two
instances, the activity per microsphere exceeded 250 Bq per microsphere with a
minimum radiolabeling efficiency of greater than 98%. The upper limit to the amount of
activity that can be radiolabeled has not been found. It is entirely possible that 300 Bq
per microsphere is achievable with a radiolabeling efficiency of 95% or more.
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The activity per microsphere is an important parameter for several reasons. The
number of microspheres should be kept low enough such that embolic effects are not
caused by the surrogate particles. As a rule of thumb, the maximum number of surrogate
particles that would be injected into a patient would be 1 million. The amount of F-18
bound to the microspheres must be sufficient to produce clinically acceptable images
within a relatively short scan time. The activity of 1 million microspheres is listed in
Table 3 and is sufficient activity for clinical PET imaging. The large amount of activity
bound to the microspheres also would allow the clinician to reduce the amount of F-18
microspheres to less than a million while still having enough activity to produce
acceptable images.
The amount of F-18 required to produce acceptable clinical PET images can be
estimated by considering the following. The American College of Radiology (ACR) has
published detailed instructions on how to test the image quality of a PET scanner using
the ACR PET phantom [55]. The phantom is designed to produce images with similar
characteristics representative of a human liver being imaged with F-18 FDG. The
amount of activity used in the ACR PET phantom varies from 0.33 mCi to 1.68 mCi of
F-18. The radiolabeling results presented in Table 3 indicate that a million microspheres
would provide activity equivalent to what is used during imaging of the ACR PET
phantom.
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Table 3: Amount of F-18 that was radiolabeled to hydroxyapatite microspheres.

Date of Experiment Run
Microsphere Type

8/29

8/31

I

Activity per microsphere
(Bq)
Activity of 1 million
microspheres (mCi)

9/7

9/12

9/21

9/21

10/12

10/12

2/2

I

I

II

I

I

I

II

II

10

253

175

185

169

29

269

113

102

0.27

6.84

4.73

5.01

4.55

0.78

7.27

3.06

2.75

In summary, the ceramic hydroxyapatite microspheres have a capacity for binding
significant amounts of F-18 from a [F-18] NaF solution. The radiolabeling is rapid and
robust. Changes in a variety of parameters did not appear to greatly affect the adsorption
rate or the radiolabeling efficiency. The radiolabeling efficiency does not seem to be
overly sensitive to parameters such as pH, initial activity concentration or other
parameters surveyed in these experiments.

B.

In Vitro Binding Stability

1.

Introduction
After the microspheres had been radiolabeled, tests were performed to determine

how well the F-18 was bound to the microspheres. The binding stability of the
radiolabeled F-18 to the microspheres was tested in the presence of a variety of materials.
These materials included de-ionized water, 0.9% NaCl saline, phosphate buffered saline
(PBS), bovine serum, and whole mouse blood. The materials of particular interest were
the blood and blood products. Some investigations have shown that blood can remove
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bound F-18 from resin microspheres [19]. These experiments were performed to help
determine if similar results could be expected with hydroxyapatite microspheres.

2.

Methods
The in vitro binding stability experiments were performed by applying a series of

washes to the radiolabeled microspheres. The microspheres were left in the same
polypropylene centrifuge tube used for the radiolabeling. A wash was performed by
adding the test material to the microspheres. The volume of the test material was usually
5 mL. The mixture was then agitated and in some instances allowed to sit for a period of
time. Then the mixture was centrifuged to force the microspheres into the tip of the
centrifuge tube. The supernatant above the hydroxyapatite pellet was drawn off.

It was

critical to avoid drawing microspheres into the pipet tip. Care was taken to not get too
close to the microsphere pellet when drawing off the wash fluid. Approximately 0.5 mL
of liquid was typically left on the hydroxyapatite pellet. After the wash fluid was
removed, material for another wash would be added to the reaction vial and a new round
of washing was started. The material drawn off during a wash was measured in the dose
calibrator. Aliquots of constant volume (50 µL) were collected in the PerkinElmer
vials. The aliquot vials were collected and placed into a rack and measured with the
Wizard2 automated counting system.
The different types of material that were used included 0.9% sodium chloride
saline. The phosphate buffered saline (PBS) solution used was Gibco PBS pH 7.4 (1X),
1000 mL container, Lot 1843259. Bovine serum, B9433, 100 mL container, lot 16A041,
was purchased from Sigma-Aldrich. Whole mouse blood was obtained from a mouse
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that had been sacrifice as part of a research study that was unrelated to this study. The
volume of the blood was 0.8 mL. De-ionized water is available from a tap in the lab.
When new wash material was added to the mixture, there was no activity in the
fresh wash material. Any residual fluid with the hydroxyapatite pellet was from the
previous wash or remaining supernatant from radiolabeling. The addition of the fresh
material dilutes the residual fluid. As the F-18 disassociates from the hydroxyapatite
microspheres, the activity concentration in the wash material increases and may reach an
equilibrium concentration. At this point, the removal of the adsorbed F-18 from the
microspheres may slow or stop until fresh unsaturated material is added. This does not
mimic the process in an animal. In the animal model, there is a constant flow of fresh,
unsaturated material. If the F-18 is removed from the microspheres and deposited
elsewhere in the body, such as the skeletal system, the activity concentration in the blood
may never reach a saturation level. Even at low removal rates, the constant removal may
result in a significant amount of activity removed over time.
Early in vitro stability experiments were done at the pH that the unit dose was
delivered. In these cases, the measured pH remained in the 5.6 to 6.1 range. During
these early experiments it was noticed that a small, but possible significant, the amount of
F-18 was disassociating from the hydroxyapatite. A possible reason that the F-18 was
continually being removed was found in the vendor literature. There was a strong
recommendation that when working with CHT ceramic hydroxyapatite microspheres, the
pH should be greater than 6.5. It was possible that the acidic conditions were
contributing to the removal of the F-18 from the microspheres. Later experiments were
done with materials that kept the pH above 6.5. Increasing the pH of the in vitro
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experiments also brought the pH closer to the physiologic pH of 7.4 for closer modeling
of the conditions in the animal model.

3.

Results
Figure 26 shows the percent activity bound to the microspheres during washing.

The results are also presented in Figure 27 which has an expanded vertical axis for easier
visualization of the data. The start of the washing phase was considered to be time zero.
At this time, 100% of the activity was considered bound to the microspheres. In general,
the results were favorable
Percent Activity Bound to Microspheres During Washing
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Figure 26: Activity bound to microspheres during washing with a variety of materials.
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In most cases, more than 92% of the initial activity remained bound to the
microspheres even after several hours of washing. The amount of F-18 that was being
removed during each wash was a small fraction of the total activity bound to the
microspheres. For instance, in one case the CHT was washed in deionized water for 3
hours and then bovine serum for an additional 1.8 hours. At the end of the washing, 93%
of the initial activity was still bound to the CHT.

Percent Activity Bound to Microspheres During Washing
100

8-31-17 Type I /
Deionized H2O
8-31-17 Type I / Whole
Mouse Blood
9-7-17 Type I / Bovine
Serum
9-7-17 Type I /Deionized
H2O
9-12-17 Type II /
Deionized H2O
9-21-17 Type I Non Cit /
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9-21-17 Type I Cit / PBS
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Figure 27: This is the same data as previous figure. Vertical axis has been expanded for better data
visualization.
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Table 4: Results of In Vitro Testing of Stability of Radiolabel.

8/29
Microsphere
Type
Wash material
Wash duration
(hours)
Wash volume
(mL)
Average wash
rate (mL/hour)
Percent F-18
remaining on
microspheres
Percent F-18
removed in wash
Second Wash
Wash material

Wash duration
(hours)
Wash volume
(mL)
Average wash
rate (mL/hour)
Percent F-18
remaining on
microspheres
Percent F-18
removed in wash

8/31

9/7

9/12

9/21

I

I

I

II

I

0.9%
NaCl
Saline

0.9%
NaCl
Saline

D.I.
Water

D.I.
Water

0.2

1.7

3.1

1.1

1.4

3.0

20.0

35.0

17.0

15.0

12.1

11.2

99.6

96.8

0.4

Icitrated

PBS

10/12 10/12
I

II

PBS

PBS

1.2

4.9

2.0

25.0

15.0

23.8

20.0

15.2

18.3

12.6

4.9

10.1

97.3

95.9

97.3

98.5

97.8

85.4

3.2

2.7

4.1

2.7

1.5

2.2

14.6

Mouse
Blood
+0.9%
NaCl
Saline

Bovine
Serum

3.0

1.7

4.0

1.8

1.8

25.0

15.0

15.0

0.6

14.4

3.8

8.1

96.4

93.3

95.6

97.7

0.3

4.0

1.7

0.8
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PBS

9/21

Bovine Bovine
Serum Serum

In general, the binding of F-18 appeared stable in blood products. Results with
bovine serum and whole mouse blood show that the initial activity remained bound to the
microspheres hours after the washing phase of the experiments began.
In some of the experiment runs, more than one type of wash material was used.
For instance on 8-31-2017, the first four washes were done with 0.9% NaCl saline over
the course of 1.18 hours. Afterwards, approximately 0.8 mL of whole mouse blood was
added to approximately 1 mL of 0.9% NaCl saline and used as a wash. The results from
the mouse blood were favorable. The hydroxyapatite was washed in whole mouse blood
for 3 hours. During this time the mixture was agitated an allowed to sit. At the end of
the wash, 1.8 mL of blood was withdrawn. Measurements indicate that the blood
removed 0.35% of the activity that was present on the hydroxyapatite at the beginning of
the blood wash.
The two runs with the most rapid disassociation of the F-18 from the
microspheres occurred with Type II microspheres. These are the 9-12-17 run with deionized water as the wash agent and the 10-12-17 run with PBS as the wash agent. In the
9-12-17 run 4% of the activity was removed from the Type II microsphere using 17 mL
of de-ionized water. In the previous experimental run on 9-7-17, only 2.7% of the
activity had been removed from Type I microspheres using 35 mL of de-ionized water
and washing for nearly three times the length of time used for washing on 9-12. This
suggests that the Type II microspheres disassociate F-18 more readily than Type I
microspheres. The Type II microspheres are the more porous of the two types. Whether
the porosity or some other factor makes the Type II microspheres more susceptible to F18 loss is unknown.
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The 10-12-2017 run with the Type II microspheres is notable in that it has most
rapid disassociation of F-18 from the microspheres. This is the same experimental run
that had the anomalous radiolabeling rate. There was something unusual about this run
but unfortunately a conclusive reason is not available. Detector errors are unlikely since
dose calibrator and Wizard2 gamma counter measurements are in agreement.
Contamination of the unit dose is unlikely since the unit dose from PETNET was
split into two doses. One dose was used to radiolabel the Type I microspheres, the other
was used for the Type II microspheres. As previously mentioned, it is possible that there
was a mix up in the phosphate buffered saline (PBS). It would be a simple matter to test
this theory. A radiolabeling run and a wash run can be performed with 10x PBS to see if
the results seen in the 10-12-17 Type II run is reproduced.
The Type I CHT microspheres were likely the best choice for use in an animal
model. The in vitro stability data was used to test the quality of the radiolabel prior to
injection into an animal. During preparation of the F-18 microspheres for injection into
an animal, the labeling efficiency was checked. It was known that at 15 to 20 minutes
after the addition of F-18 NaF to the microspheres, the labeling efficiency should be in
excess of 95%. When the radiolabeling appeared satisfactory, the microspheres were
then to be washed in PBS for 30 minutes. It was expected that the F-18 binding should
remain stable with more than 96% of the activity remaining on the microspheres. If the
F-18 binding was not stable as in the case of the 10-12-17 Type II run, then the amount of
activity remaining on the microspheres was expected to be less than 96% at the 30 minute
time point. This testing allowed for easy differentiation between useful and poorly
labeled batches of microspheres.
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C.

In Vivo Binding Stability

1.

Introduction
The binding stability of the F-18 radiolabeled microspheres was tested in an

animal model. PET imaging was used to assess the amount of F-18 that disassociated
from the microspheres. Rats were chosen as the animal model for this investigation. Rats
and mice have been previously used in similar investigations with success [19], [39],
[50]. For this pilot study, the protocol was submitted to the Institutional Animal Care and
Use Committee (IACUC). The protocol number, 18-200686-HSC was assigned by the
Office of Animal Care Compliance (OACC) upon approval. Permission was given to use
up to four female rats. At the beginning of the animal experiment, the intent was to seek
approval to expand the study if the radiolabel microsphere performance was acceptable.
The animal model was used to investigate the stability of the radiolabel in the
entire organism. This includes the myriad of tissue types and physiological processes
present in a living rat. Whole body PET imaging is very sensitive and can detect small
amounts of activity in the skeleton or other locations in the body. PET imaging over time
can quantify the amount of F-18 that is disassociating from the hydroxyapatite
microspheres. The sequence of procedures was anesthesia, I.V. injection, imaging and
then euthanasia.
The F-18 radiolabeled microspheres were injected into the tail vein of a rat. As
expected, the microspheres collected in capillaries of the lungs which are the first
biological filters downstream from the injection site. If the F-18 remained bound to the
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microspheres, then PET imaging would show all of the radioactivity localized in the
lungs. If the F-18 was removed from the microspheres, the likely place for free F-18
fluoride ions to localize was in the skeletal system. It is well known that free F-18 in the
blood tends to collect in the skeletal system. F-18 sodium fluoride is routinely used for
performing clinical PET skeletal imaging of humans.
The solution volume for injection into the rat was expected to be 200-400
microliters. This volume contained approximately 200 to 500 micrograms of
hydroxyapatite particles. This is equivalent to 60,000 to 120,000 microspheres. The
microspheres have a nominal diameter of 20 microns. The number of microspheres is not
unusually large. For instance, Selwyn et al. injected 100,000 resin microspheres into the
tail vein of a rat without incident[19]. The resin microspheres were 30 microns in
diameter.
There is evidence that hydroxyapatite in lungs is stable in vivo while
hydroxyapatite in liver may not be stable. In an investigation by Jauregui-Osoro et al.
2011, they injected several forms of hydroxyapatite radiolabeled with F-18 [50]. The
size of the particles used were 200 nm or less. This group found that the nanoparticles in
the lungs were stable. There was evidence that nanoparticles that migrated to the liver
and spleen were taken up by phagocytic cells of the reticuloendothelial system. Over a
period of four hours, these nanoparticles then gradually released F-18 which then
collected in the skeleton. These nanoparticles are two orders of magnitude less than the
microspheres used in this investigation. Microspheres that are 20 µm in diameter are
much less likely to be incorporated into phagocytic cells [51]. In addition, our imaging
study occurred within 2 hours, not 4 hours after injection [50].
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2.

Methods
Hydroxyapatite microspheres were labeled with F-18 using the methods described

in the radiolabeling section. To begin, 4 milligrams of Type I CHT microspheres was
measured and placed in a 15 mL centrifuge tube. The volume of the [F-18] NaF unit
dose was increased with PBS. A 50 µL aliquot was removed from the [F-18] NaF
solution. The pH of the initial solution was measured with BAKER-pHIX pH test strips
and found to be 6.7. The [F-18] NaF was then added to the centrifuge vial containing the
microspheres. At the time that the F-18 NaF was added to the microspheres, the [F-18]
NaF activity was 3.33 mCi. The residual dose was 0.25 mCi. After the fluid was added,
the vial was capped and the mixture was agitated by hand for approximately one minute.
The contents were centrifuged at 2500 RPM for 3 minutes. After centrifuging, a 50 µL
aliquot was removed. The aliquot was measured in the dose calibrator and found to have
an activity of 2.0 µCi. This was 12 minutes since the addition of the [F-18] NaF to the
microspheres. The aliquot activity measurement was compared to the 50 µL aliquot
taken from the [F-18] NaF prior to the addition of the NaF to the hydroxyapatite. The
activity of this aliquot measured 58.9 µCi. Calculation showed that the activity in the
supernatant was approximately 3% of the initial activity (2/58.9 = 0.03). The process
was repeated. The mixture was agitated by hand and centrifuged. At 19 minutes since
the addition of the [F-18] NaF to the microspheres, a 50 µL aliquot was again taken from
the supernatant. The activity of the aliquot was measured in the dose calibrator and
found to be 0.40 µCi. This activity was compared to the aliquot taken prior to addition of
the NaF to the microspheres. This measurement indicated that the activity of the
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supernatant was 0.6% of the initial supernatant activity. At this point, the amount of F-18
that could be bound to the microspheres had likely reached a maximum. Subsequent
calculations indicate that the labeling efficiency was greater than 99%.
The mixture was agitated and centrifuged again to separate the microspheres from
the supernatant. Approximately 1.8 mL of supernatant was then removed from the
centrifuge vial. The microspheres and approximately 0.2 mL of supernatant remained in
the centrifuge vial. The microspheres were washed by adding 5 mL of phosphate
buffered saline (PBS). The mixture was shaken by hand and then centrifuged at 2500
RPM for 3 minutes. An autopipette was used to remove 5 mL of the wash liquid. The 5
mL of wash liquid measured 10.66 µCi. A second wash was performed by adding 5 mL
of PBS to the microspheres, agitating and centrifuging. After being centrifuged, the
second wash was removed and measured in the dose calibrator. The second wash
measured 8.53 µCi. The centrifuge tube contained 1 mL of liquid and the hydroxyapatite
microspheres. The activity of the centrifuge tube was 1.89 mCi. The activity in wash 2
was approximately 0.4% of the total activity. At this point, it was decided to draw the
dose for injection into the rat.
The animal that was selected was a small female Sprague Dawley rat that was
acclimated one week before being used. The animal weighed 170.3 grams prior to
injection. The animal was anesthetized with isoflurane which is an inhalant. The initial
dose was 4% to 5% at induction with oxygen and then 1.5% to 2% for maintenance of the
anesthetized state.
The volume of the fluid containing the microspheres was adjusted to 2.0 mL with
PBS. The pH of the fluid was measured with BAKER-pHIX pH test strips and was
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found to be 7.0 to 7.3. A dose volume of 400 µL was drawn into a 1 mL TB syringe and
measured in the dose calibrator. The measured activity was 223 µCi. The microspheres
were slowly injected into the tail vein of the rat. The residual activity in the syringe was
measured in the dose calibrator and found to be 66 µCi. The injected activity at the time
of injection was 151 µCi. The injected volume contained 9.56 x 104 microspheres. The
activity per microsphere at the time of injection was 58 Bq/microsphere. The activity per
microsphere was lower than initially planned for. However, the number of microspheres
that were injected was close to what was specified in the protocol. The protocol called
for 120,000 to 100,000 microspheres to be injected. Due to delays and the short half-life
of F-18, the total injected activity was lower than initially planned. However, the activity
proved to be sufficient for imaging.
Within a few minutes of injection, the rat was placed into the bed for the PET
scanner. The animal was then transferred to the scanner and positioned for imaging.
The imaging was done with a LabPET small animal PET scanner. The scanner is built as
a ring of detectors. Each detector contains LYSO and LGSO crystals coupled to an
avalanche photodiode. The scanner has a 10 cm transaxial field of view.
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Figure 28: LabPET small animal PET scanner

The first PET imaging series was started 12 minutes post-injection. This was a
10-minute acquisition of a single bed position. The animal was positioned with the lungs
in the field of view. The second imaging series was another 10-minute lung acquisition
started 32 minutes post-injection. The third series was a whole-body acquisition that was
started 43 minutes post-injection. The entire imaging time for the whole-body scan was
25 minutes. A total of 4 bed positions were scanned. The imaging time was roughly
divided equally over the 4 bed positions. The fourth series was another whole-body
acquisition that was started 79 minutes post-injection. The entire imaging time was 25
minutes over 4 bed positions. The last PET series was another 10-minute acquisition of
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the lungs. This was started 109 minutes post-injection. After the PET acquisitions, that
animal was transported to the small animal SPECT/CT. Here a helical whole body CT
was acquired with a scan time of 6 minutes and a pitch of 1.5. The tube voltage was 65
kVp. The tube rotation time was 0.5 seconds. CT images were reconstructed using
filtered backprojection with a Ram-Lak filter. The PET images were reconstructed using
the MLEM iterative reconstruction algorithm using 10 iterations.
The animal was euthanized immediately after imaging with no chance for
recovery in accordance with the approved IACUC protocol. This was performed by
increasing the isoflurane to 5% with oxygen. The animal was monitored for signs of
death. The animal carcass was held for radioactive decay in storage.

3.

Results
The results of the rat imaging showed that all of the injected activity remained in

the lungs. Careful examination of the Maximum Intensity Projection (MIP) images show
that the accumulation of F-18 in the skeletal system was not present. Figure 29 shows
two views of the rat. This whole-body acquisition took a total of 25 minutes to acquire.
The start time was 79 minutes post-injection. The feature labeled A in Figure 29 is a
fiducial created by placing 50 µL of radioactive fluid in a 0.2 mL PCR tube. The activity
of the source was 54 µCi 20 minutes prior to injection. The feature labeled B in Figure
29 is the injection site in the tail. This is not unusual. Residual activity is often found at
injection sites. The intensity scale was set in Figure 30 to maximize visualization of
activity. Note that the activity in the tail is easier to see. Activity was not visible in the
joints or bones.
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Figure 29: Coronal and oblique views of rat. Feature A is a small fiducial. This was 48 µCi of F-18 in 50
µL of fluid in a 0.2 mL PCR vial at the time of injection. Feature B is residual activity in the injection area.
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Figure 30: Two views of rat. Intensity has been set to maximize visualization of activity.

A Volume of Interest (VOI) was drawn around the lungs in the three lung-only
series. The CT with the lung VOI overlaid in green is shown in Figure 31. The same
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lung VOI was drawn in all three lung series to collect data to form a time-activity curve
(TAC) for the lungs shown in Figure 32. The TAC for the lungs has been corrected for
radioactive decay. The amount of F-18 in the lungs appears to remain constant over the
time the animal was scanned which was approximately 2 hours.

Figure 31: CT of rat with lung VOI in green. The same VOI was used in all five series to form TAC
curve.
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Decay-Corrected Time Activity Curve for Lung VOI
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Figure 32: Time Activity Curve for lung VOI. Each data point is placed at the start time for the imaging
series. The activity has been decay corrected to the time of injection. The error bars represent one standard
deviation from the mean.

A similar process was followed to draw a volume of interest in the spine. The
spine VOI was used to measure potential uptake in the skeleton over the imaging time.
The CT with the spinal VOI overlaid in cyan is shown in Figure 33. The decaycorrected, data was used for the TAC shown in Figure 34. The amount of activity in the
spine VOI appears to remain constant over the imaging time of nearly 2 hours.
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Figure 33: CT of rat with spinal VOI shown in cyan. The same VOI was used in all three lung-only series
to collect data for a TAC for the spine.
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Figure 34: Time Activity Curve for spine VOI. Each data point is placed at the start time for the imaging
series. The activity has been decay corrected to the time of injection. The error bars represent one standard
deviation from the mean.

It was suspected that he measured uptake in the spine VOI was likely due to
scatter from the lungs and fiducial. Three additional VOIs were drawn to measure the
background uptake values. The background VOIs are shown in Figure 35. A plot of all
VOIs is shown in Figure 36. The uptake in the spine VOI is on the same order of
magnitude as the background VOIs. Note that the mean uptake is measured in activity
concentration (Bq/mL) not activity. The uptake in the background VOIs appears to
correlate with the proximity to the lungs and fiducial. This confirms that the uptake
measured in the spine VOI was likely due to scatter.
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Figure 35: Three background VOIs colored magenta are shown labeled as 1, 2, and 3. The intensity of the
PET image has been increased to maximize visualization of scatter.
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Comparison of Lung and Spine to Background
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Figure 36: The decay-corrected uptake for the lungs, spine and background VOIs are shown. The uptake
in the spine VOI is similar to the uptake in the background VOIs.

The conclusion from the animal imaging is that the F-18 radiolabel is stable in
vivo over two hours post-injection. The particles did not appear to breakdown or
fragment during imaging. Due to the microspheres size and shape, the expected
localization of the particles was in the lungs. The activity per microsphere is sufficient
for animal imaging and would provide enough activity for translation into imaging in
humans.
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III.

Image-Based Dosimetry

A.

Monte Carlo Modeling
The advantage of full, direct Monte Carlo modeling is that it is possible to closely

model the physical processes underlying radiation transport and interaction with matter.
Monte Carlo modeling naturally takes into account the stochastic nature of radiation
interactions. The primary disadvantage is the computation time required to achieve
results with acceptable levels of statistical uncertainty. Depending on the needs of the
user, the computation time required for Monte Carlo may not be an issue. Typically,
there is one to two weeks between the administration of the surrogate Tc-99m MAA and
the administration of the Y-90 microspheres. If a similar time frame is assumed for a
positron-emitting surrogate, the use of the Monte Carlo method should be sufficient.
When the clinical situation requires faster dose calculation for treatment planning,
methods to reduce computation time can be explored.
Other methods of performing image-based dosimetry will be briefly described. In
the dose point kernel (DPK) method, a dose point kernel is a three-dimensional
representation of the absorbed dose delivered by a point source in a homogeneous
medium. The activity in a material can be considered an array of point sources weighted
by the activity of each source. In the process of convolution, the dose to a point of
interest is the superposition of all of the doses delivered by the array of point sources
surrounding the point of interest [8], [56], [57]. The dose point kernel method can be
performed rapidly with the Fast Fourier Transform or Fast Hartley Transform[8]. The
use of a transform speeds the dose calculation but imposes a constraint that the kernel is
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spatially invariant. The use of the DPK method for calculation of dose at
inhomogeneities such as tissue interfaces can result in significant errors.
The S-voxel method was developed within the MIRD schema [57]. The
following equation is used for calculation of dose:
𝑁

𝐷𝑜𝑠𝑒𝑘 = ∑ 𝐴̃ℎ ∙ 𝑆(𝑣𝑜𝑥𝑒𝑙 𝑘 ← 𝑣𝑜𝑥𝑒𝑙 ℎ)

(3.1)

ℎ=0

In this method, a source voxel, h, has an associated cumulated activity, 𝐴̃ℎ . The
dose to voxel k from the activity in voxel h is the product of the cumulated activity in
voxel h multiplied by an S-value that describes the dose delivered to voxel k by the
activity in voxel h. The total dose delivered to voxel k is the sum of the dose contributed
by N surrounding voxels. In MIRD publication 17, three-dimensional arrays of S-values
are tabulated for a variety of isotopes and voxel sizes. The S-voxel method is susceptible
to error and inhomogeneities such as tissue interfaces.
The Local Deposition Model (LDM) is based on the assumption that the dose in a
voxel is due to the activity within a voxel [56]. The activity within a voxel is multiplied
by a LDM constant to produce a dose per voxel. Image blurring will spread the activity
associated with a source. This will in turn, spread the dose calculated with the LDM.
These other methods are primarily used to reduce the computation time for imagebased dose calculations. In some instances, the Monte Carlo modeling has been done
before hand. When applied to a specific dosimetry problem, the method relies on a
straightforward look-up and summation. Full Monte Carlo modeling can handle
inhomogeneities such as tissue interfaces but at the expense of large computational time.
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There were several considerations when choosing which Monte Carlo program to
use. The ability to use medical images as input to the Monte Carlo program was
important. Other considerations included having examples, good documentation and
established validation in the literature. Programs that were considered included MCNP,
GEANT4, and Penelope.
GATE (GEANT4 Application for Emission Tomography) is an open source
toolkit based on the Monte Carlo program GEANT4 [58], [59]. GATE is designed for
modelling emission tomography imaging systems such as Positron Emission
Tomography (PET) and Single Photon Emission Computed Tomography (SPECT). The
user is able to use medical images in the MetaImage format as input. The output options
from GATE also include images in the MetaImage format. These images contain a
header (.mhd file extension) and raw data (.raw file extension). An open-source program
with the name “VV” can be used to convert tomographic image series in the DICOM
format into the MetaImage format [60]. Once in the MetaImage format, the tomographic
data can be imported into GATE and used as a non-radioactive object or as a voxelized
source of radioactivity. The ability to import PET image data and to use the PET object
as a source of radiation in the Monte Carlo simulation was a large factor in the selection
of GATE as the modeling software of choice.
In addition to the ability of GATE to handle medical images, there is a pre-built
version of GATE available. The program vGATE is a virtual machine that is configured
to run GATE version 7.2. Using Oracle VirtualBox software, a virtual machine is created
that runs Ubuntu Linux 14.04 LTS and GATE version 7.2. All Linux and GATE
dependencies are pre-built which save considerable time in program setup.
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1.

Validation of GATE Using Dose Point Kernels for Monoenergetic Electrons

a)

Introduction
It was necessary to evaluate the accuracy of GATE 7.2 for photon and electron

transport and interactions. One method used was the calculation of dose point kernels
(DPK). A dose point kernel is a representation of absorbed dose as a function of distance
from an isotropic point source in a homogeneous medium[57]. They have simple and
reproducible geometry. This facilitates comparison of results from different Monte Carlo
programs. The dose point kernels calculated in this study were compared to those
published in the literature.

b)

Methods
A survey of the literature showed many reports on the calculation of dose point

kernels for beta emitters [61]–[63]. However, only a few were found that actually
contained numerical data [64]–[66]. In one of these publication, the Monte Carlo
program FLUKA was used to produce DPKs for monoenergetic electrons in the energy
range from 10 keV to 3 MeV in water and compact bone [65]. These same researchers
also calculated DPK data for beta-emitting radionuclides of interest in medical
applications. These radionuclides include Y-90, Sr-89, I-131, Sm-153, Lu-177, Re-186
and Re-188. The FLUKA results were then compared to DPKs generated by other Monte
Carlo programs, specifically, PENELOPE v2008, ETRAN, GEANT4.8.2, and MCNPX
2.5.0. Comparison of GATE results to FLUKA results were especially beneficial in that
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by comparison to FLUKA, a secondary comparison to other Monte Carlo programs was a
result. All of these results proved to be useful in establishing confidence in the GATE
7.2 results. Another researcher, Seltzer, provided DPK data for monoenergetic electrons
in the energy range 20 keV to 20 MeV [66]. This researcher used the Monte Carlo code
ETRAN to calculate the scaled point kernel values. A subset of this data is available in
Appendix C, Table C.1 of ICRU publication 56 [67].
In this study, GATE 7.2 was used to calculate the scaled dose point kernels for
monoenergetic electrons in water. The method used was very similar to that outlined in
the FLUKA study [65]. The scaled dose kernel was calculated by creating a set of
concentric shells surrounding a monoenergetic point source. The concentric shells were
of equal thickness. The outer surface of the largest shell was at a radius of 1.5 RCSDA.
The range of electrons in water using the continuous slowing down approximation is the
value RCSDA. For an electron initial kinetic energy, the value of RCSDA was found in the
NIST ESTAR database [68]. There were 60 shells for each scaled dose point kernel.
Each shell had a thickness of 0.025RCSDA. The innermost shell had an inside radius of 0
cm and an outer radius of 0.025RCSDA centimeters.
For the calculation of each scaled DPK, a total of 107 primary particles were used
in the GATE simulation. The energy that was deposited in each shell was tallied and
reported in the results from GATE. Using 107 primaries resulted in a typical reported
uncertainty of 0.1% or less for energy deposited in each shell for all shells within a radius
of 0.9RCSDA. The scaled dose point kernel can be expressed as shown in equation 3.2. In
the literature, this formula is also referred to as the scaled point kernel. The scaled dose
point kernel, F, is a function of the scaled radius, r/RCSDA, which is dimensionless.
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𝐹(𝑟/𝑅𝐶𝑆𝐷𝐴 ) =

𝛿𝐸(𝑟)/𝑇0
𝛿𝑟/𝑅𝐶𝑆𝐷𝐴

(3.2)

The scaled dose point kernel, F, is the fractional energy divided by the scaled
shell thickness, r/RCSDA. The fractional energy for a shell is calculated as the energy
deposited in the shell, E(r), divided by the total electron kinetic energy, T0. For
monoenergetic electrons, the total electron kinetic energy, T0, in a simulation run is
simply the initial electron kinetic energy, E0, multiplied by the number of primary
electrons used in the simulation, Np.
𝑇0 = 𝐸0 ∙ 𝑁𝑝

(3.3)

The scaled shell thickness is the shell thickness, r, divided by RCSDA. In the
GATE simulations performed for monoenergetic electrons, each shell was 0.025RCSDA
thick and was located between radius r and r + r.
In GATE, for charged particle interactions, the user must set a range cut-off using
the SetCutInRegion command. Below this threshold, secondary particles will not be
generated. For the monoenergetic scaled DPK runs, range cuts were set to 0.005 mm for
electrons. In water, this range corresponds to a kinetic energy of 4.3 keV. The lowest
energy scaled DPK calculated was for 10 keV electrons.
Users of GATE have several choices regarding the statistical output. GATE can
provide an output file for energy deposition and dose to voxels. Additional files can be
selected that contain what the User’s Manual describes as “dose squared” or “energy
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squared”. The “energy squared” value is not the square of the sum but is actually the sum
of the squares of each individual energy deposition.

2
“Energy Squared” = ∑𝑁
𝑖=1 𝐸𝑘,𝑖

(3.4)

Where 𝐸𝑘,𝑖 is the energy deposited in voxel k in history i. The quantity N is the
total number of primary particles [69].
2

𝑠𝐸𝑘

2
∑𝑁
∑𝑁
1
𝐸𝑘,𝑖
𝑖=1 𝐸𝑘,𝑖
= √
⌊(
) − ( 𝑖=1
) ⌋
𝑁−1
𝑁
𝑁

(3.5)

In addition to the “energy squared” output file, there is an uncertainty file. This
has an estimate of the relative uncertainty. The uncertainty reported by GATE is the ratio
of the estimated standard error of the mean energy, 𝑠𝐸𝑘 , divided by the mean energy
[69]. For a given volume, the uncertainty for the energy deposited is also the same
numerical value as the reported uncertainty for the dose. There are more detailed
discussions of the statistical uncertainty in GATE [69]–[71]. It was confirmed by
calculations that the statistical output is indeed being calculated by the method presented
here.
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Figure 37: Uncertainty reported for energy deposited in shells of scaled dose point kernel for 10 keV
monoenergetic electrons. 0.8RCSDA occurs at boundary between shells 36 and 37. The distance 0.9RCSDA
occurs at the boundary between shells 36 and 37.

Figure 37 shows the uncertainty reported by GATE for a scaled DPK run with 107
simulated primary electrons. In this case, the distance, 0.8RCSDA occurs at the boundary
between shell 32 and shell 33. The distance 0.9RCSDA occurs at the boundary between
shell 36 and 37. The uncertainty is less than 0.1% at a distance less than 0.8RCSDA from
the origin. Within the distance 0.9RCSDA the uncertainty is less than 0.12%. At distances
past 0.9RCSDA the uncertainty increases rapidly.
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c)

Results

Using GATE, scaled dose point kernels were calculated for the following
monoenergetic electron sources in water: 10 keV, 50 keV, 100 keV, 500 keV, 1 MeV and
2 MeV. When comparing different transport algorithms, differences often becomes more
prominent at lower energies [65]. For this reason, the lower energy scaled DPK’s were
of particular interest. It is relatively straightforward to change the physics processes used
for modeling within GATE. The physics processes are specified using the physics list
builder command. The default physics constructor for Geant4 10.02 is “emstandard”.
The modeling can be switched to the Penelope physics models by using the physics list
builder “empenelope”.
A comparison study of the results generated with empenelope and
emstandard_opt3 was performed. For the relatively high-energy electrons at 1 MeV,
there was little difference between the calculated scaled DPK values. However, the
calculated scaled DPK for 10 keV electrons were very different for the two physics
packages.
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GATE 7.2 (emstandard_opt3) vs FLUKA
Scaled DPK 10 keV Monoenergetic Electrons in Water
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Figure 38: Scaled Dose Point Kernel for 10 keV Electrons. Results from GATE 7.2 compared to FLUKA.
The physics package used was “emstandard_opt3”.

In Figure 38, the 10 keV scaled DPK calculated with GATE using
emstandard_opt3 is compared to the same scaled DPK calculated by Botta et al. using the
FLUKA code.
The agreement between the 10 keV scaled DPK values was poor. In Figure 39,
“empenelope” was used as the physics list builder replacing “emstandard_opt3”.
Otherwise, all other parameters were identical. The resulting scaled DPK for 10 keV
electrons was in much better agreement with the scaled DPK calculated by FLUKA.
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GATE 7.2 (Penelope Physics) vs FLUKA
Scaled DPK 10 keV Monoenergetic Electrons in Water
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Figure 39: Scaled Dose Point Kernel for 10 keV Electrons. Results from GATE 7.2 compared to FLUKA.
The Penelope physics package was used.

The FLUKA group had also published a comparison of their 10 keV scaled DPK
results to other Monte Carlo programs including PENELOPE v2008, ETRAN,
GEANT4.8.2, and MCNPX 2.5.0. The agreement among the different programs was
acceptable. It was decided that “empenelope” would be used for the calculation of all
subsequent electron scaled DPKs.
The following figures display the other monoenergetic scaled DPK’s in water
calculated by GATE and compared to results reported for FLUKA. Seltzer provides
DPK values calculated with ETRAN for monoenergetic electrons [66]. These data were
also used for comparison. The comparisons are shown in the following images.
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Figure 40: Scaled DPK for 50 keV monoenergetic electrons in water as calculated by GATE, ETRAN and
FLUKA.

Figure 41: Scaled DPK for 100 keV monoenergetic electrons in water as calculated by GATE, ETRAN
and FLUKA.
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Figure 42: Scaled DPK for 500 keV monoenergetic electrons in water as calculated by GATE, ETRAN and
FLUKA.

Figure 43: Scaled DPK for 1 MeV monoenergetic electrons in water as calculated by GATE, ETRAN and
FLUKA.
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Figure 44: Scaled DPK for 2 MeV monoenergetic electrons in water as calculated by GATE, ETRAN and
FLUKA.

Percent differences between GATE and FLUKA were calculated for values in
which data was available. The percent difference was calculated using the formula
below.
𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝐷𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 = 100 ∙

(𝐹𝐺 − 𝐹𝐹 )
𝑚𝑖𝑛(𝐹𝐺 , 𝐹𝐹 )

(3.6)

𝐹𝐹 and 𝐹𝐺 are the scaled point kernel values for a given shell. 𝐹𝐺 was the value
calculated by GATE 7.2 and 𝐹𝐹 was calculated with FLUKA. The results are shown in
Table 5. A comparison of this data to similar data in Botta et al. shows that the
magnitude of the percent difference between the GATE results generated in this study are
the same magnitude found when comparing scaled DPK values among other Monte Carlo
programs [65].
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Table 5. The percent discrepancy between GATE 7.2 results and FLUKA results [65]. Also shown is the
average percent difference within 0.9RCSDA.

Electron
Kinetic
Energy

Maximum Percent
Discrepancy Within
0.8 RCSDA

Maximum Percent
Discrepancy Within
0.9 RCSDA

Average Percent
Discrepancy Within
0.9 RCSDA

10 keV
50 keV
100 keV
500 keV
1 MeV
2 MeV

12.3
-6.2
-7.7
2.4
4.0
3.5

-13.2
13.5
19.6
2.8
6.6
7.7

4.3
3.4
5.0
1.4
2.0
2.3

d)

Conclusions
What was consistent throughout the literature was that there was never perfect

agreement between different Monte Carlo programs. There was acceptable agreement
between monoenergetic scaled DPKs calculated with GATE 7.2 and other DPK values
presented in the literature. This confirms that electron transport and interactions are
being handled adequately. These results verify that the energy deposition in thin water
targets is accurately modeled.

2.

Calculation of Dose Point Kernel for Y-90

A necessary step prior to calculation of the dose point kernel for a beta-emitting
radionuclide is to find the energy spectrum for the emitted beta particles. Several
candidate spectra were found. A Y-90 beta spectrum evaluated in this study was
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published by Eckerman et al. [72]. Subsequently, another Y-90 beta spectrum was found
in ICRU publication 56 [67]. Another Y-90 beta spectrum was generated by Dr. Doug
Simpkin. This was provided via personal communication by Dr. Reed Selwyn.
An initial survey of the data showed that the number of data points in each
spectrum differed. The spectrum from Eckerman had 20 energy bins. The spectrum
from ICRU 56 had 40 energy bins. The spectrum from Simpkin had 200 energy bins. To
compare the spectra, the data was rebinned and normalized. Specifically, the 40 bins of
the ICRU 56 data were collapsed into 20 bins and renormalized. Likewise, for the
Simpkin data, the 200 energy bins were collapsed into 20 bins and renormalized. The
comparison of the data found that the agreement between the spectra was good.
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Figure 45: Comparison of beta spectra for Y-90. These were the three spectra that were considered for use
in the subsequent Y-90 simulations. For purposes of comparison, the ICRU 56 data and the data from
Simpkin were rebinned.

The primary difference between the spectra is in the energy resolution. The effect
of the different energy resolution on the DPK calculation was examined. The beta energy
spectrum from Simpkin is essentially the same as the beta energy spectrum from
Eckerman. The spectrum from Simpkin has 200 data points while that of Eckerman has
20.
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Figure 46 shows the Y-90 DPK calculated with the 20 bin Y-90 spectrum from
Eckerman et al. and the Y-90 DPK calculated with the 200 bin Y-90 spectrum from
Simpkin. Other than the different beta spectra, the input files for GATE were identical.
The result is essentially the same DPK. Within X90, the maximum difference between the
two spectra was less than 0.6%. X90 is the radius of a sphere in which 90% of the energy
is deposited [65].
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Figure 46: Scaled DPK for Y-90 calculated with 20 point Y-90 beta spectrum from Eckerman et al. and a
200-point beta spectrum from Simpkin. Within X 90, the maximum difference between the two DPK was
less than 0.6%.

The scaled dose point kernel for Y-90 was calculated using GATE. To facilitate
comparison, the same geometry that was used for calculation of the Y-90 scaled DPK
with FLUKA was used for GATE [65]. The geometry for the Y-90 DPK was similar to
the geometry used for the monoenergetic electrons. A simulation was created of an
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isotropic point source of Y-90 placed in water. A series of concentric shells were defined
about the point source and the energy deposited in each shell was calculated using
GATE. The shell thickness was set to 0.1 mm which is approximately 0.02X90. The
inner surface of the outer most shell was at 2(r/X90). The result was 107 shells. Within
the supplemental material of their paper, Botta et al. provide values for the scaled dose
point kernel, F, for approximately half of their shells. Simpkin and Mackie also provided
data for scaled point kernels using EGS4 [61]. The data for the three dose point kernels
is plotted in Figure 47.

119

Y-90 DPK in Water
Calculated with Multiple Monte Carlo Programs
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Figure 47: Scaled DPK for Yttrium-90 as calculated with GATE, FLUKA and EGS4.

3.

Validation of GATE and Image-Based Dosimetry
Experiments were performed to assess the use of GATE and PET data for image-

based dosimetry. PET images were acquired with fluorine-18. This is the same
radionuclide used to label the surrogate microspheres.
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a)

Case 1: Homogeneous water-filled phantom

In the United States, clinically used PET scanners are coupled to a Computed
Tomography (CT) scanner to form a dual-modality PET/CT. The CT provides highresolution anatomic imaging which aids in the localization of PET activity within the
patient. The CT also provides important attenuation properties of the patient. Each
volume element, voxel, in a CT image has an associated Hounsfield Unit (HU). The
value of the HU for a voxel is measured by the transmission of the x-ray beam through
the material in the voxel. The gray scale map of the HU values is the data used to
produce the CT images. The formula for the Hounsfield Unit is shown below. The linear
attenuation coefficient of the voxel is 𝜇. The linear attenuation coefficient for water is
𝜇𝑤𝑎𝑡𝑒𝑟 . For a water-filled voxel, the Hounsfield Unit value will be close to zero.

The

electron density of the material in a voxel is the primary determinant for the attenuation
properties of the voxel. In general, for material denser than water, the HU value will be
greater than one. For material less dense than water, the HU will be less than one. The
CT images are a 3-dimensional map of the attenuation properties of the object being
scanned.

𝐻𝑈 = 1000 ×

𝜇 − 𝜇𝑤𝑎𝑡𝑒𝑟
𝜇𝑤𝑎𝑡𝑒𝑟

(3.7)

The CT data is used to correct the PET images for attenuation. When a positron
undergoes annihilation with an electron, two photons are formed each with 511 keV of
energy. These photons travel in opposite directions. For a “true” count to be recorded by
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the PET imaging system, both photons must be recorded by detectors within the ring of
the PET scanner. Thus, both photons must make it out of the object being scanned.
There is a significant probability that attenuation can occur to the photons as they travel
through material. The probability of attenuation depends on the material and path length
through the material being traversed. Annihilation photons born deep in the patient have
a higher probability of attenuation than annihilation photons produced near the surface of
the patient. The CT data is used to correct the PET images for attenuation. Typically,
two set of clinical PET images are produced for each patient, an attenuation-corrected set
of images and a non-attenuation-corrected set of images.
For the Siemens PET/CT scanners used in this study, the vendor provides a
“uniformity” phantom for use in PET quality control. The uniformity phantom is a
hollow, plastic cylinder which is filled with water. The vendor states that the volume of
the cylindrical phantom is 6.283 liters. When preparing the phantom for imaging, a
positron-emitting radionuclide such as F-18 is carefully measured in a dose calibrator.
The activity of the F-18 and the time of measurement are recorded. The radionuclide is
then added to the water in the phantom and mixed. The result is a cylinder containing a
uniform distribution of a known activity concentration. The activity concentration is
typically expressed in Becquerel per milliliter (Bq/mL). In the experiment presented
here, the activity injected into the uniformity phantom was 1.624 mCi (60.08 MBq) of F18.
The dose calibrator used to measure the F-18 was a Capintec 15R (SN#152530)
located in the hot lab at University of New Mexico Hospital. The instrument was a
clinically used dose calibrator that met regulatory quality control. The F-18 calibration
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number had been previously set using the NIST traceable Ge-68/Ga-68 source described
in the radiolabeling section. The calibration sheet for the source is presented in Appendix
A.

Figure 48: Cylindrical uniformity phantom mounted on bracket at end of patient table. The uniformity
phantom is used for quality control of the PET/CT scanner. Phantom volume is 6.283 liters. Scanner is a
Siemens Biograph 16 PET/CT.

Prior to scanning, the phantom was mounted on to the holder at the end of the
patient bed as shown in Figure 48. The whole body scanning protocol that would be used
on a patient was used to scan the phantom. A scout image was acquired with CT. The
PET acquisition was set for a stop condition of 100 million counts per bed position. Two
bed positions were used to completely image the phantom in the axial direction. The
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phantom was then scanned using CT. The scan parameters were 120 kVp, 48 mA and a
tube rotation time of 0.5 seconds. The images were 3 mm thick reconstructed using the
B31f reconstruction kernel. The PET scan was then started and the start time was
recorded. The PET was acquired with a 168 x 168 matrix and a Gaussian convolution
kernel with FWHM of 5 mm. The PET images were reconstructed with a slice thickness
of 3 mm using an OSEM2D iterative reconstruction algorithm using 2 iterations and 24
subsets. The CT data was used to produce attenuation-corrected PET images.
The resulting attenuation-corrected PET and CT image DICOM series were
imported into the program VV and converted into MetaImage format. The MetaImage
PET and CT image series were then imported into GATE. The CT series was used as
the “patient”. In the GATE simulation, the attenuation properties in a voxel is
determined by the Hounsfield Unit (HU) for that particular voxel. The HU values are
determined by the CT scan as described previously.
The PET image was imported into GATE and converted into a voxelized source.
The activity of the simulated source was independent of the activity used to produce the
PET image. In the GATE simulation, it is possible to use an activity that is different than
the activity used to produce the PET images. It was also possible to change the
radionuclide to one different from the radionuclide used to acquire the PET image. For
instance, in this case, 1.624 mCi of F-18 was used to produce the PET images. Within
GATE, the source was then assigned an activity of 30.1 Bq of Y-90. The assigned
activity was determined by the number of primary particles used in the GATE simulation.
In this case, the primary particles were electrons created using the Y-90 energy spectrum.
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In this way, the voxelized source within GATE was converted to a uniform cylinder with
a volume of 6283 mL containing 30.1 Bq of Y-90.
The PET images were essentially a three-dimensional map of the relative F-18
activity within the phantom.

This relative activity map was converted into a voxelized,

three-dimensional map of the relative Y-90 activity. This was done by setting the source
emission to be electrons with kinetic energy determined by the Y-90 beta energy
spectrum. For this initial experiment, the number of electrons emitted was set to 107. For
the Monte Carlo run, the number of primary particles is equivalent to the integrated
activity, Ac. For a permanent implant, Ac is the total number of disintegrations between
calibration time t = 0 and t = infinity is given by the following equation. The integrated
activity Ac, is equivalent to the cumulated activity 𝐴̃ℎ in the MIRD schema.
∞

𝐴𝑐 = ∫ 𝐴(𝑡)𝑑𝑡

(3.8)

0

𝐴𝑐 = 𝐴0 ∙ 𝑇1/2 ∙

1
ln(2)

If Ac is set to 107 and the half-life of Y-90 is 230550 seconds, we can solve for A0:

107 = A0 x (230550 seconds) x 1.443
A0 = 30.1 disintegrations/second = 3.01 x 10-8 GBq
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(3.9)

The following relation can be used to calculate the absorbed dose delivered to the
phantom from 30.1 Bq of Y-90. Recall the volume of the phantom is 6.283 liters of
water, thus the mass of the phantom is 6.283 kg.
𝐷𝑜𝑠𝑒𝑡𝑎𝑟𝑔𝑒𝑡 (𝐺𝑦) = 49.38 ∙ [𝐴0 (𝐺𝐵𝑞)/𝑀𝑎𝑠𝑠𝑡𝑎𝑟𝑔𝑒𝑡 (𝑘𝑔)]

(3.10)

Thus,
DoseTarget (Gy) = 49.38 x [3.01x10-8 GBq/6.283 kg] = 2.363 x 10-7 Gy

A GATE run was performed using 107 primary electrons. The 20 bin beta
spectrum from Eckerman et al. was used to produce the simulated beta particles [72].
The physics package was “empenelope”. Total run time was 12489 seconds (3.47 hours)
on a laptop with an Intel Core i5-4300U CPU at 1.90 GHz.

The output of the GATE

run was a 3D dose map of the phantom. The tomographic dose image was opened in
3DSlicer software version 4.6.2. A large volume of interest (VOI) was placed into the
center of the phantom and the resulting dose in the VOI was found to be:

2.337 x 10-7 Gy ± 0.232 x 10-7 Gy

The percent difference between the calculated absorbed dose and the dose measured with
the VOI was:
100% x [(2.337-2.363)/2.363]= -1.1% ± 9.8%
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Figure 49: Voxelized dose map of uniform PET phantom displayed in 3DSlicer. The green sphere is the
volume of interest (VOI). The mean dose in the VOI is 2.337x10-7 Gy ± 0.262x10-7 Gy.

The results of this experiment confirms that GATE can be used to produce
accurate image-based dosimetry. The use of more primary particles in the GATE
simulation would reduce the associated error at the cost of increased computing time.

b)

Case 2: Inhomogeneous water-filled phantom
Image-based dosimetry in the case of a homogeneous phantom has been shown to

be accurate. The case of an inhomogeneous phantom is presented next. The activity in a
PET source must be enough to produce an acceptable image. Beyond this requirement,
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the activity used to produce the PET image is not used in the dosimetry calculations. The
issue addressed with the study of the inhomogeneous phantom was if the relative activity
distribution is maintained in the voxelized source. For instance, if a region had twice the
amount of F-18 than another region, the 2:1 ratio in activities should be maintained
throughout the Monte Carlo simulation. If the F-18 was replaced with Y-90, the resulting
dose to the two regions should still maintain the 2:1 ratio.
The initial step was to acquire a PET/CT image of the phantom. In this case, the
PET/CT was acquired during the 2016 annual survey of the Siemens mCT PET/CT at
UNM Outpatient Surgery and Imaging Services. The PET acquisition was performed
using the clinical whole body PET protocol. A 200 x 200 matrix was used with a
Gaussian convolution kernel with a FWHM of 5 mm. The time per bed position was set
to 1 minute. The slice thickness was 5 mm. The reconstruction used OSEM iterative
reconstruction with 3 iterations and 21 subsets. This included high-resolution point
spread correction (TrueX) and Time-of-Flight (TOF) PET imaging. CT imaging was
done with 170 kVp, 73 mAs, tube rotation time of 0.5 seconds and a helical acquisition
with a pitch of 0.8. The CT images were reconstructed using the B19f convolution
kernel. The PET images were corrected for attenuation using the CT data.
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Figure 50: The ACR PET phantom. The lid contains objects that enable measurement of the imaging
capability of a PET/CT scanner. A positron-emitting radionuclide is added to the bulk fluid in the phantom
and also to the ‘hot’ cylinders in the lid. The hot cylinder-to-bulk contrast ratio is 2.5:1

Figure 51: Underside view of the lid for the ACR PET phantom. The “hot’ cylinders are filled with a
positron-emitter and water. The “cold” cylinders are free of activity.
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The American College of Radiology (ACR) requires a specific model of PET
phantom is to be used for ACR PET accreditation. The PET phantom is an acrylic
cylinder with an inner diameter of 20.4 cm. The cylinder is filled with water. Prior to
scanning, a small amount of positron-emitting radionuclide is added to the bulk fluid to
produce a “warm” background. Within the large cylinder are wedge-shaped groups of
rods. The rods are made of solid acrylic and during imaging are free of radioactivity.
These “cold” rods are used to determine the spatial resolution of the PET camera.
The lid of the ACR PET phantom contains four fillable cylinders. These are the
“hot” cylinders. Prior to use, the hot cylinders are filled with a solution of positronemitter and water. The ACR provides a standard set of instructions for determining the
activity concentrations used to fill the cylinders in the lid and the bulk fluid. The activity
amounts for the cylinders and the bulk fluid is designed to be near a 2.5:1 ratio. This
contrast ratio is representative of a hot lesion in a liver. The diameters of the four hot
cylinders are 8 mm, 12 mm, 16 mm and 25 mm [55]. There are also three “cold”
cylinders that are free of radioactivity. These are cylinders containing water, air and
Teflon.
The attenuation-corrected PET images were used as the voxelized source in a
GATE simulation. The CT provided the material densities so that absorbed dose could
be calculated. The attenuation-corrected PET, non-attenuation corrected PET and CT
series of DICOM images were exported from the scanner. The open-source software
“VV” was used to convert the DICOM series into the MetaImage (*.mhd and *.raw)
format. The image below is a screen shot of the VV program with the CT image
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displayed in MetaImage format. In this case, the matrix size of the CT image was 512 x
512 x 75. The size of the image was 500 mm x 500 mm x 225 mm.

Figure 52: CT image of ACR PET phantom displayed in VV. In the axial slice, the white object at the 3
o’clock position is the Teflon cylinder. The air-filled cylinder is at the 6 o'clock position.
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Figure 53: PET image of ACR PET phantom displayed in VV. Bright object at 1 o’clock is 25 mm
diameter hot cylinder.

Figure 54: Side by side comparison of CT (left) and PET (right) of slice 62 through ACR PET phantom.
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The attenuation-corrected PET DICOM series were imported into VV and
converted into MetaImage (*.mhd and *.raw) format. The PET image had a matrix size
of 200 x 200 in the axial plane and 75 voxels in the z-axis which is parallel to the patient
bed and the axis of the phantom cylinder.
A way to check the PET and CT registration was to do a GATE run with a few
thousand monoenergetic electrons. Using relatively low-energy electrons ensured that
the particles did not move far from the point of origination. Figure 55 shows the PET
phantom with the several thousand electrons being produced. The registration was found
to be acceptable.

Figure 55: ACR PET phantom in GATE. The slice shown is through the uniformity section of the
phantom. The registration of the PET and CT images can be checked visually by running the simulation
with a few thousand monoenergetic electron with relatively low energy. Here the initial kinetic energy of
the electrons is 200 keV.
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The GATE run was performed with the Y-90 beta spectrum from Eckerman et al.
The empenelope physics package was used. The SetCutInRegion length for electrons
was set to 0.005 mm. The total number of primary electrons generated was 107. The run
time for the simulation was 12063 seconds (3.35 hours). Output included a tomographic
map of the energy deposition in the phantom and a tomographic map of the absorbed
dose in the phantom. Figure 56 shows the same slice through the cold rod region of the
phantom in the original F-18 PET image (left), in the Y-90 energy deposited image
(middle) and the Y-90 absorbed dose image (right). The number of cold rods that can be
visualized was the same in all three images. This indicates that the spatial resolution was
maintained during the conversion of the original F-18 PET image into the Y-90 PET
image. As expected the relative activity concentration of the Y-90 has produced an
energy deposition and absorbed dose distribution that closely matches the activity
distribution of the surrogate F-18 activity in the original PET data. The surrogate F-18
activity has been used to accurately map the absorbed dose produced by the Y-90.
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Figure 56: Comparison of F-18 PET (left), Y-90 Energy Deposited (middle) and Y-90 Absorbed Dose
(right). Slice was through cold rods. Note that the number of rod groups visualized was the same in all
three images. The spatial resolution has been maintained.

Figure 57: Comparison of F-18 PET (left), Y-90 Energy Deposited (middle), and Y-90 Absorbed Dose
(right). The slice was through the hot and cold cylinders. Visual assessment indicates that contrast was
maintained.

Figure 57 shows the same slice through the hot and cold cylinders displayed in the
original F-18 PET image, the Y-90 energy deposition image and the Y-90 dose image.
Notice the dose in the air-filled cold cylinder near the 6 o’clock position has a relatively
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high dose. The absorbed dose is the energy deposited per unit mass. Due to the low
mass of the air, the absorbed dose in the air-filled cylinder was relatively large.
The activity distribution in the original F-18 PET phantom was compared to the
final Y-90 energy deposition by drawing volumes of interest (VOIs) in the largest hot and
cold cylinders and comparing the values to the bulk fluid. In Figure 58, a red VOI is
drawn in the largest hot cylinder, a green VOI is drawn in the bulk fluid and a yellow
VOI is drawn in the cold, water-filled cylinder. The ratio of the activities was measured
for the F-18 PET. The ratio of the deposited energy is measured for the Y-90.

Figure 58: F-18 PET (left) and Y-90 Energy Deposited (right) and with spherical volumes of interest
(VOIs) colored yellow, green, and red.
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Table 6: Ratios of activities in F-18 PET phantom compared to Y-90 energy deposited map

Quantity
Ratio of hot 25 mm
cylinder to bulk fluid
(red/green)
Ratio of cold water
cylinder to bulk fluid
(yellow/green)

F-18 PET
(ratio of activity
concentration)

Y-90 Energy Deposited
(ratio of energy
deposited)

2.291 ± 0.225

2.236 ± 0.214

0.099 ± 0.545

0.137 ± 0.577

When the ACR PET phantom was loaded with F-18 FDG prior to scanning, the
activity concentration in the hot cylinders was 2.42 times the activity concentration in the
bulk fluid. Volumes-of-interest, (VOIs) were used to measure the activity concentrations
from the images. Using the F-18 PET images, the image-based measurement of the ratio
of the activity concentration in the hot cylinder to the bulk fluid was 2.291 ± 0.225.
Performing the same measurement on the Y-90 energy-deposited images results in a ratio
of the energy deposited of 2.236 ± 0.214. The results are in agreement within the stated
uncertainty. VOIs were also drawn and compared for the cold water cylinder and the
bulk fluid. The ratio (cold cylinder/bulk) with the PET image was 0.099 ± 0.545 while
the same ratio measured on the Y-90 energy-deposited image was 0.137 ± 0.577. The
quantities were in agreement within the stated uncertainty. It is apparent that the subject
contrast was maintained from the surrogate F-18 PET phantom to the dosimetric
calculations for Y-90 using GATE.

137

Figure 59: Spherical VOIs placed for signal-to-noise ratio measurements in F-18 PET (left), Y-90 Energy
Deposited (middle) and Y-90 Absorbed Dose (right). Each VOI was identical 5 cm diameter sphere.

Table 7: Signal-to-noise ratios for the same VOI drawn on the three image types

Signal-to-Noise
Ratio

F-18 PET Image

Y-90 Energy
Deposited Image

Y-90 Absorbed
Dose Image

6.52

6.59

6.59

The signal-to-noise ratio (SNR) for the F-18 PET images were in good agreement
with the Y-90 energy-deposited images and Y-90 absorbed-dose images produced by
GATE. The GATE images actually had a slightly higher SNR. This may be due to
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smoothing of the noise in the simulated Y-90 tomographic maps. The energy deposition
due to the activity distribution has the effect of smoothing or blurring the activity
distribution [8].
In conclusion, F-18 PET data can be used as a surrogate for Y-90 activity
distribution. A Monte Carlo program such as GATE can use the F-18 activity
distribution to produce accurate maps of the absorbed dose from Y-90.

B.

Dosimetry Verification with Film

1.

Introduction
The goal of the phantom and film experiment was to verify the absorbed dose

calculated by imaging of a surrogate radionuclide and Monte Carlo modeling. Fluorine18 was placed into a phantom which was imaged on the Siemens Biograph 40 mCT
PET/ST scanner at OSIS. Y-90 was then introduced into the phantom and the absorbed
dose to water in the phantoms was measured using radiochromic film. The film had been
calibrated using a Sr-90/Y-90 source with a known output. The measured absorbed dose
in the water was compared to the absorbed dose calculated from the PET/CT images and
Monte Carlo modeling.
The average range of the Y-90 beta in water is 2.5 mm and the maximum range in
water is 11 mm. In materials of interest such as water and tissue, there may be a large
change in dose within a small spatial range. The steep dose gradient can make beta dose
measurements very challenging. A dosimeter with a high spatial resolution may be
required to sample the dose at different distances from the source. Radiochromic film

139

dosimetry is an established method of performing dose measurements from a betaemitting source.
When radioactive microspheres are injected into a patient during
radioembolization, the microspheres collect into capillaries and remain fixed in position.
This produces a volumetric distribution of radioactivity. When radioactive microspheres
are added to an aqueous solution, density differences cause the microspheres to settle to
the bottom of the container. The hydroxyapatite microspheres used in these experiments
would visibly clear from a solution within a few minutes. The microspheres then collect
at the bottom of the container into a compact radioactive mass while the remaining
aqueous solution is clear of radioactive material. This distribution is not similar to that
expected in an organ such as the liver. To create a distribution that is more “life-like”
several ideas were explored.
For the phantom imaging experiments, a homogenous system that was large
enough to avoid partial volume effects was desired. Partial volume effects begin to affect
the apparent activity of an object when the object size is three times the Full Width and
Half Maximum (FWHM) of the reconstructed image resolution or smaller [73]. In
general, the FWHM of PET scanners is approximately 5 mm. Thus, the size of an object
in the phantom should be 1.5 cm or greater to avoid partial volume effects.
The simplest case was to use an aqueous solution of radioactive material and not
use radiolabeled microspheres. This avoids the settling problem. When the F-18 and Y90 are in solution, it is much easier to make homogeneous mixtures of different sizes.
At the time of this study proposal, it was possible to acquire surplus resin SIRSpheres. However, the physicians at our facility have moved towards almost exclusive
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use of glass TheraSpheres. Due to the nature of how the TheraSpheres are ordered and
delivered, there were no surplus TheraSpheres available. It was necessary to purchase a
source of Y-90. For this experiment, an amount of Y-90 yttrium chloride was purchased
from a commercial supplier of radionuclides.

2.

Methods
There are several factors that were considered when selecting the type of film to

use. The film had to be sensitive in the expected range of absorbed dose. A waterproof
film was selected to allow for direct measurement of radioactive fluid. Ultimately, the
water-proof property of the film was not utilized. The thickness of the active emulsion
layer and the protective layer were considered. The film active layer and protective
layers were symmetric. There was not a front or back to the film. The film was
transparent.
The film that was chosen was Gafchromic™ EBT-XD made by Ashland Global
Holdings Inc. Lot number 08021701. The expiration date of the film is February 2020.
The film is temperature sensitive. The film package contains a high-temperature warning
strip to alert the user if the ambient temperature exceeded the vendor recommended
value. EBT-XD contains an inner active layer 25 um thick situated between two
polyester outer layers. Each outer layer is 125 um thick. The active layer contains a
material that when exposed to radiation forms a blue polymer that has an adsorption
maxima near 633 nm. The polyester layers protect the inner layer and make the film
waterproof if the cut edges are kept dry. EBT-XD film is transparent. Exposure to
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radiation causes the active layer to change color and darken. The amount of film
darkening is dependent on the absorbed dose to the film.
Complete instructions on the use of Gafchromic film for dosimetry are available
from Ashland [74]. The scanner used was an Epson model 11000XL, serial number
040059. This is a model recommended by Ashland for performing dosimetry with
Gafchromic films. . The acquisition software was Epson Scan v.3.49A running in
Windows 7. The film vendor provides recommendations for the scanner settings. Scans
were done in professional mode with 48-bit color, 72 dpi resolution and color correction
off. The scanned images with saved in the lossless format TIFF.
The film response is orientation dependent. The long side of the film can be
parallel or perpendicular to the scan direction. An orientation should be chosen and films
should be scanned in a consistent manner. In this experiment, the film was typically
marked with a permanent marker to indicate orientation.
A 2 mm thick glass compression plate was used to keep the film flat against the
scanner bed. The same glass plate was always used in the same orientation when
scanning calibration and measurement films
A well-known effect exists known as the lateral response artifact [75]. For flatbed scanners, the readout response varies in the direction lateral or perpendicular to the
scan direction. Thus, for scanning of the film, the same lateral position should be used.
For scans in this study, care was taken to ensure that objects of interest were centered
laterally with respect to a reference line in the scan direction
The film response changes with time. After exposure the film was stored in a
dark area. This allowed post-exposure changes in the active layer polymer to stabilize.
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At least 24 hours was allowed between exposure and reading. Exposure times and
reading times were recorded.
If the scanner has not been idle for more than an hour, the film manufacturer
recommends that several “warm up” scans be performed prior to meaningful scans. The
warm up scans equilibrate the light source which helps provide a consistent color.
The TIFF images were imported in the program ImageJ version 1.51k. Here the
color images were separated into the three component channels, red, blue and green. The
red channel image was used for dosimetry. However data from all three data channels
can be used.
A film calibration curve was created with a calibrated source of Y-90. Calibrated
Sr-90/Y-90 ophthalmic applicators with known dose rate have been used with
success[76]. To produce an exposure, the applicator was placed on the film for a
measured amount of time. The dose delivered to the film was determined by the product
of the dose rate and the exposure time. The darkening of the film was measured with a
flatbed scanner as described previously. By exposing film over the expected range of
doses, a calibration curve was built. In subsequent measurements, the absorbed dose to
the film was determined by measuring the amount of film darkening and comparison to
the calibration curve.
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Figure 60: Amersham SIA.20 Sr-90/Y-90 ophthalmic applicator being withdrawn from its case. The
source is the disk at the end of the rod.

The Sr-90/Y-90 source that was used was a model SIA.20 planar ophthalmic
applicator produced by Amersham International, serial number 0547ML. Details
regarding the construction of the source were difficult to find. The NCS 70 report states
that the Sr-90 is embedded in silver with an active diameter of 9 mm and has a stainless
steel container with a thickness of 0.05 mm at the face [77]. The parent nuclide Sr-90 has
a relatively long half-life of 28.78 years. It decays by beta-minus decay into Y-90 which
has a much shorter half-life. The parent and daughter nuclides are in secular equilibrium.
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The applicator was calibrated in 2008 by the Accredited Dosimetry Calibration
Laboratory (ADCL) at the University of Wisconsin-Madison. The Average Surface
Absorbed Dose Rate to Water was found to be 0.39 Gy/sec over the central 4 mm
diameter region of the source face. The dose rate was dependent on the activity of the Sr90 source. The source strength was decay corrected using the same half-life that was
used by the ADCL. The ADCL used a half-life of 28.78 years. The decay-corrected
source strength at the time of this experiment was found to be 0.31 Gy/sec. The
calibration uncertainty stated by the ADCL was +/-11%. A copy of the calibration
documentation is in Appendix B.
A stopwatch was calibrated using the Direct Comparison Method described in
Special Publication 960-12 published by the National Institute of Standards and
Technology (NIST) [78]. The stopwatch was a Timex 1440. When performing the
Direct Comparison Method, a phone call was placed to NIST located in Fort Collins
Colorado U.S. The phone number for this location is (303) 499-7111. At the start of
each minute, there is a voice recording announcing the upcoming time. Then a 1500 Hz
tone marks the beginning of the minute. At the start of this tone, the stopwatch was
started. The stopwatch was stopped when the tone of the next minute was heard. After
the stopwatch had been stopped, the elapsed time was recorded. A total of 20
measurements were performed. The mean elapsed time was 59.998 seconds with a
standard deviation of 0.068 seconds. For a 60 second measurement, the percent error
associated with the error in time measurement is 0.11%. For a 10 second measurement,
the percent error associated with the error in time measurement is 0.68%.
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In the phantom, the radiochromic film is separated from a mixture of water and
Y-90 by a “beta-window” made of a thin layer of polyester film. The film that was used
was 0.001” (25 µm) thick “Dura-lar” sold by Grafix Plastics.

Figure 61: Depiction of the detector arrangement. During calibration, the Y-90 source was an ophthalmic
applicator. During the experiment, the Y-90 source was Y-90 chloride in water.

There were several advantages of the phantom arrangement shown in Figure 61.
When assembled, the film was in close proximity to the Y-90 and water source. The
weight of the water placed a gentle pressure against the beta window that pushes out air
from between the beta window and the radiochromic film. Another advantage is that the
radiochromic film can be placed and removed without direct contact with the Y-90
source. This minimizes the likelihood of contamination of the EBT-XD film with Y-90.
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It was also easy to remove the film if the phantom was going to be imaged with CT. The
radiochromic film was to be removed prior to exposure to x-rays from the CT.
Each phantom was made from a Nalgene brand 500 mL jar. A hole was cut in the
lid to allow access for the radiochromic film and solid water plug. The beta window was
made by creating an inner-lid ring out of thick polyester. The thin (0.001”) Dura-lar of
the beta window was glued across the ring with contact cement. Green PVC cement was
used to waterproof the seal between the thin film and the support ring. Figure 62 shows
the phantom with the outer lid off. The inner support ring and beta window are visible.
The phantom is filled with 400 mL of water and blue food coloring. Silicone grease was
used to seal the support ring and the phantom body.

Figure 62: Phantom 4 with lid off showing the support ring and 0.001" thick polyester beta-window. The
phantom contains 400 mL of fluid and blue food coloring. Silicone grease is used to seal the support ring
and body of phantom.
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In Figure 63, the blue outer lid has been installed. A 40 mm diameter paper disk
is shown taped to the solid water plug. The paper disk was used during leak testing of the
phantom. When making measurements, a disk of EBT-XD film would be taped into the
same position as the paper disk.

Figure 63: Phantom with outer lid on. There is a 40 mm diameter paper disk taped to the solid water plug.
During use, the radiochromic film was taped to the solid water plug in the same manner.

Figure 64 shows the completely assembled phantom. When containing
radiochromic film, the film would be sandwiched between the beta window and the solid
water plug. To begin exposure to the film, the entire phantom was inverted so the beta
window and plug was at the bottom of the phantom. The water/Y-90 mixture formed a
layer that was approximately 4 cm thick above the radiochromic film.
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Figure 64: Phantom completely assembled. The solid water plug and film are in place. The final step in
deployment of the phantom is to invert the entire assembly.

To perform calibration of the EBT-XD for a phantom, a strip of Gafchromic EBTXD was cut from the original sheet. The unexposed strip was scanned with the Epson
11000XL. The radiochromic film was placed on a plate of solid water. This is the same
solid water material that was used for the plugs backing the beta-windows. The Dura-Lar
beta window from the phantom was placed over the radiochromic film. The SIA.20
applicator was then placed on the beta window. Irradiation of the radiochromic film
occurred through the beta window of each phantom. Thus, each phantom had a
calibration curve. In this manner, variation in thickness or other non-uniformity in the
beta window material was accounted for in the calibration curve. The exposure time for
each exposure was recorded using the calibrated stopwatch. The dose delivered to the
calibration strip was determined by multiplying the dose rate to water at the face of the
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Sr-90/Y-90 source by the exposure time. As noted previously, the error associated with
the stopwatch measurements was low (±0.7% or less) compared to the error stated by the
ADCL laboratory for the dose rate from the applicator (±11%)
The film vendor recommends a geometric progression of exposure time. The
exposure time for the calibration curve generally followed the progression, 10, 15, 23, 34,
51, 76 and 114 seconds. This is a geometric progression with a common ratio of 1.5.

Figure 65: Strips of EBT-XD radiochromic film used for calibration of phantom 4. The dark circles are
where the film was exposed with the Sr-90/Y-90 calibration source. The absorbed dose ranged from 3.6 to
38.6 Gy.

A region on interest (ROI) tool in ImageJ version 1.51k was used to measure film
darkening. A circular region of interest 4 mm in diameter was placed in the center of
each exposed area on the calibration film. The ROI tool was used to measure the mean
pixel value and the standard deviation of the pixel value in the ROI.
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Figure 66: Red channel image of one of the calibration films for phantom 4. A green circular ROI is
shown on the exposed area J.

The calculated absorbed dose and the mean pixel data were entered into
MATLAB R2016a 64-bit version (MathWorks, Inc.). The curve fitting application in
MATLAB was used to fit a curve to the data. Figure 67 shows a curve fit to the
calibration data for phantom 4.

Figure 67: Screenshot from MATLAB curve fitting application showing the curve fit using a rational
function.
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In the literature are several recommendations regarding the form of the equation
used to fit the calibration data Some suggestions, including those published by the film
vendor, have been to use the general class of equations known as rational functions [79],
[80]. The form of the rational function that was used for this study was:
𝐹(𝑥) =

𝑎 + 𝑏𝑥
𝑐+𝑥

(3.11)

The absorbed dose, x, is the product of the irradiation time and the dose rate
produced by the applicator. The measured film response, i.e. darkening, is F(x). The
curve fitting application in MATLAB was used to find the three parameters, a, b and c.
This specific form was discussed in a paper by Micke et al. [81]. The EBT-XD white
paper describes several advantages of using rational functions to fit the calibration data
[80]. These include:
1. Rational functions are simple to invert. The equation above can be rewritten
as:
𝑥=

𝑎 − 𝑐𝐹(𝑥)
𝐹(𝑥) − 𝑏

(3.12)

2. The functions plateau at high doses much like the film response.
3. The functions can be fitted with few data points. The vendor recommends six
to eight data points with the doses spaced in a geometric progression.
The calibration curve for phantom 4 is shown in Figure 68.
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Calibration Curve for Phantom 4
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Figure 68: Calibration curve for phantom 4. The uncertainty in the absorbed dose is dominated by the
uncertainty in the dose rate of the Sr-90/Y-90 applicator.

Due to the lack of availability of surplus Y-90 microspheres, it was decided to use
Y-90 yttrium chloride. A source of Y-90 yttrium chloride, YCl3, was purchased from
Eckert and Ziegler, lot number YGB07. The calibration activity was 30 mCi at noon
12:00 EST 2018-Mar-05. The vendor stated that the uncertainty of the activity was
within ± 10%. The source contained 1 mL of Y-90 chloride in 0.04 M HCl in a 10 mL P6
vial. The material was carrier free.
The Y-90 yttrium chloride was originally going to be divided among three
phantoms, however, delays necessitated using only two phantoms. The material was
divided among the phantoms on March 6, 2018. This was the day after the calibration
153

date. The activity in the vial was to be used to find the best calibration potentiometer
setting for the dose calibrator. The activity in the vial was calculated using the decay
equation. The vial was placed into the CRC-7 dose calibrator and the calibration
potentiometer was adjusted until the dose calibrator reading matched the activity of the
Y-90 yttrium chloride solution. Previous work with SIR-spheres in the same dose
calibrator provided an estimate of the calibration potentiometer setting that would work
for the P6 vial. In addition, a paper on dose calibrator setting for Y-90 ibritumomab
tiuxetan also provided an estimated calibration setting for Capintec dose calibrators [82].
It was found that a calibration potentiometer setting of 43 provided an accurate activity
reading for the Y-90 chloride in the P6 vial. At this setting, the displayed activity needed
to be multiplied by a factor of 10 to arrive at the correct activity.
Activity measurements were done on the 20 mCi range setting. The calibrator
was zeroed prior to measurement. The Y-90 chloride had been delivered in a volume of
1 mL. To split the activity between the two phantoms, the volume of the fluid in the vial
was increased to 2 mL. To do this, a solution of 0.04 M HCl was created and 1 mL was
injected into the vial. The activity was measured again in the CRC-7 dose calibrator with
a calibration setting of 43. It was found that the activity was significantly different that
the activity reading with a fluid volume of 1 mL. This indicated that the dose calibrator
activity reading was sensitive to the fluid volume in the vial. A 5 mL syringe was used to
withdraw 1 mL of fluid. This brought the fluid volume in the P6 vial back to 1 mL. The
activity in the P6 vial was remeasured. The activity in the 5 mL syringe was determined
by subtracting the initial activity measurement at 1 mL from the post-withdrawal activity
measurement also with a 1 mL volume in the vial. The activity in the syringe was
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injected into phantom 4. The residual activity in the syringe was measured and found to
be 0.00 mCi. It was determined that a total of 11.2 mCi had been injected into the jar
phantom. The remaining 1 mL of fluid in the P6 vial was withdrawn from the vial with
the 5 mL syringe. Non-radioactive solution of 0.04 M HCl was used to bring the volume
in the P6 vial back to 1 mL. The residual activity in the P6 vial was then measured. The
activity in the 5 mL syringe was determined by subtracting the post-withdrawal
measurement of residual activity from the pre-withdrawal measurement. Note all activity
measurements were done with the fluid volume in the P6 vial at 1 mL to reduce variation
in the dose calibrator readings due to geometric effects. The activity in the 5 mL syringe
was added to phantom 2. The residual activity was measured and found to be 0.00 mCi.
The activity placed into phantom 2 was 9.7 mCi.

Figure 69: 10 mL P6 vial containing 30 mCi of Y-90 yttrium chloride in 1 mL volume.
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Disks of EBT-XD film had been scanned and cut prior to loading the phantoms.
Each disk of film was 40 mm in diameter. The maximum range of the Y-90 beta
electrons in water is 11 mm. Thus, the planned area for reading the film was the central
portion of the film that was 11 mm from the edge. This was the circular central area 18
mm in diameter.
After the phantoms had been loaded with Y-90 chloride, a disk of radiochromic
film was taped to the solid water plug. The film and plug were placed against the beta
window and taped into position. The phantoms were then inverted. The time of
inversion was recorded.

Figure 70: Phantoms 4 and 2 in the inverted position. Each phantom had the radiochromic film and solid
plug on the underside.
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The length of time that the radiochromic film was exposed to the solution of Y-90
chloride and water determined the absorbed dose to the film. The integral of the activity
equation between the two times could be used to determine the total number of
disintegrations in the water solution. The total number of disintegrations multiplied by
the average energy per disintegration provided the total energy deposited in the water
solution. The energy deposited in the water was then divided by the mass of the water to
determine the absorbed dose to the water. The radiochromic film had been calibrated
with the ophthalmic applicator through the beta window to a known dose delivered to
water at the surface of the applicator.
A GATE run was performed using the same geometry and phantom as used to
expose the film. The input to the GATE run were PET and CT DICOM series acquired
on the Siemens Biograph mCT PET/CT at OSIS. The phantom had 61 µCi of the
surrogate radionuclide, F-18 added to 400 mL of water. One bed position was used. A
stop condition of 100 million counts was set. A 400 x 400 matrix and a Gaussian filter
with a 2.0 FWHM was used. Time-of-Flight and TrueX with an iterative method using 1
iteration and 21 subsets were used to reconstruct the PET series. A CT was acquired for
attenuation correction. The CT was acquired using 120 kVp, 40 mAs, helical acquisition
with a reconstructed slice thickness of 5 mm.
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Figure 71: Phantom in position for scanning in Siemens Biograph mCT PET/CT.

The software ‘VV’ was used to convert the DICOM PET and CT images into the
MetaImage format for importation into GATE. The number of primary electrons used in
the GATE run was equivalent to the number of disintegrations as discussed previously in
the section on the homogenous phantom. A GATE run was performed with 107 primary
electrons produced using the Y-90 beta energy spectrum. This is equivalent to an
integrated activity of 30.1 Bq of Y-90. The absorbed dose to water for this activity was
measured by opening the absorbed dose tomographic map in 3DSlicer and placing a VOI
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in the water near the area where the radiochromic film was exposed. The absorbed dose
to the water in the phantom was scaled according to the number of disintegrations that
occurred in the water. The number of disintegrations that occur between two points in
time is given by the following equation.
𝑡2

𝑇𝑜𝑡𝑎𝑙 𝐷𝑖𝑠𝑖𝑛𝑡𝑒𝑔𝑟𝑎𝑡𝑖𝑜𝑛𝑠 = 𝐴0 ∫ 𝑒 −𝜆𝑡 𝑑𝑡

(3.13)

𝑡1

Here A0 is the calibration activity at the calibration time = 0. The times t1 and t2 are
referenced to the calibration time and lambda, λ, is the decay constant.
If the radiochromic film was to be immersed in the water, the dose to the film
would be nearly equal to the absorbed dose to the water. When the film dosimeter is
moved to the bottom of the phantom, the geometry changes from 4π geometry to 2π
geometry. The absorbed dose in the film will be half of the absorbed dose in the water.
GATE runs were performed in which the attenuation properties of the EBT-XD
film were examined. The run set up is shown in Figure 72. It was found that the dose to
the active region of the film was nearly equal to the dose to the bulk water. To examine
the effect of moving the film dosimeter to the edge of the phantom. The same run
depicted in Figure 72 is shown in Figure 73. However, for the second case, only one
water-filled cylinder contained Y-90. The dose to the radiochromic film was half of the
dose delivered when the film was completely surrounded by Y-90 and water. Thus, the
dose measured with radiochromic film in the geometry used in the phantoms was half of
the absorbed dose in the bulk fluid. Small changes due to attenuation in the beta window
have been taken into account by calibration of the film through the beta window with the
Sr-90/Y-90 applicator.
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Figure 72: GATE model of two water-filled cylinders (green and white) each containing Y-90. A 4 mm
disk of EBT-XD film is surrounded by an annulus of film. The two water cylinders were moved into
contact with the film prior to starting the simulation. This models the submersion of the film into a waterfilled phantom.

Figure 73: Gate simulation in which only one of the water cylinders (green) contains Y-90. This models
the situation where the film is against the Y-90 water phantom and has a solid water backing.
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Figure 74: CT of the jar phantom in the inverted position. The solid water cylinder is seen at the bottom of
phantom.

Figure 75: PET scan of fluid in jar phantom. Approximately 61 µCi of F-18 was added to the jar phantom.
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As an example, the film disk D1 was deployed on the phantom 1.33 hours after
the calibration time. The film remained on the phantom for 21.38 hours. Thus t2 is 1.33
hours plus 21.38 hours. The calibration activity was 11.21 mCi or 4.15x108 Bq. The
number of disintegrations that occurred during this time was 2.80x1013. To calculate the
he absorbed dose using the GATE results, the dose from 107 was scaled to the number of
disintegrations occurring during the deployment of the film. The scaling factor was then
multiplied by the absorbed dose read from the VOI placed in the GATE-generated
tomographic dose map. This is shown in Figure 76. In this case the scaling factor was
2.80x106. The absorbed dose to water measured with the VOI from the GATE run was
3.80x10-6 Gy ± 0.23x10-6 Gy. The scaled dose to the bulk water was 10.64 Gy ± 0.64
Gy.

Figure 76: Tomographic absorbed dose map output from GATE run. A total of 10 7 primary Y-90 electrons
were used. A VOI shown in blue was used to determine the absorbed dose to the water in the central
region of the phantom.
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The bulk dose measured with GATE was in agreement with the calculated value
of 10.41 Gy ± 1.04 Gy calculated by integrating the activity over the irradiation time and
multiplying by the mean energy per disintegration. The dose to film disk D1 was 50% of
the absorbed dose to the bulk water. Using the scaled bulk dose calculated using GATE,
the dose to disk D1 was:
Dose to D1= 0.5*(10.64 Gy ± 0.64 Gy) = 5.32 Gy ± 0.32 Gy.

Table 8: Comparison of GATE calculated results to analytically calculated results.

Film
ID

D1
D3
D5
D6
D8

Time PostCalibration
When Film
Deployed
(hours)
1.33
22.75
49.98
73.82
142.10

Time Spent on
Phantom 4
(hours)

Calculated dose
delivered to film
(Gy)

21.38
27.15
22.36
67.20*
47.70

5.20 ± 0.52
5.09 ± 0.51
3.20 ± 0.32
5.94 ± 0.59
2.21 ± 0.22

Calculated dose
delivered to film
using GATE
results
(Gy)
5.32 ± 0.32
5.21 ± 0.31
3.29 ± 0.20
6.16 ± 0.37
2.26 ± 0.14

*Daylight savings time, March 11, 2018 taken into account

The first film radiochromic disks were deployed on phantoms 4 and 2. The films
were checked the next day. At that time, it was found that phantom 2 had leaked and the
film disk was contaminated with Y-90. An attempt to clean the Y-90 from the film disk
was unsuccessful. Phantom 2 was retired and not used for the remainder of the
experiment. The first film disk that was removed from phantom 4 was disk D1. After
removal, the film was placed in an envelope and placed in a dark area to stabilize. The
next disk, D3, was taped to the solid water and deployed on phantom 4.
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3.

Results
After irradiation, the film was placed in a dark area to equilibrate. After at least

24 hours, the film was scanned on the Epson 11000XL. The same methods used to scan
and measure the calibration films were used for the film disks. The TIFF image was
imported into ImageJ. The ROI tool was used to draw circular ROIs in the center of the
disk image. Each circular ROI was 18 mm in diameter. A total of 5 film disks were
acquired. All were irradiated on phantom 4.

Figure 77: Five EBT-XD film disks that were irradiated on phantom 4. Going from left to right: D1, D3,
D5, D6 and D8.

Figure 78: Film disk D8 next to one of the calibration films for phantom 4.

Figure 79: Red channel image of film disks with 18 mm x 18 mm circular ROI placed on disk D5.
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Table 9: Comparison of dose measurements from radiochromic film and analytically calculated doses.

Film
ID

Time PostCalibration
When Film
Deployed
(hours)

Time Spent
on
Phantom 4
(hours)

Calculated
dose delivered
to film
(Gy)

Measured
dose
delivered to
film (Gy)

D1
D3
D5
D6
D8

1.33
22.75
49.98
73.82
142.10

21.38
27.15
22.36
67.20*
47.70

5.20 ± 0.52
5.09 ± 0.51
3.20 ± 0.32
5.94 ± 0.59
2.21 ± 0.22

11.22 ± 1.32
20.63 ± 2.84
16.26 ± 2.28
43.33 ± 5.26
15.87 ± 1.89

Delta
(Measured
Dose –
Calculated
Dose)
(Gy)
6.02
15.54
13.07
37.39
13.66

*Daylight savings time, March 11, 2018 taken into account
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Figure 80: Results for radiochromic film experiment. Comparison of absorbed dose measured with film to
calculated dose.
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The calculated dose to the film and the measured dose to the film were not in
agreement. In general, the absorbed dose measured by the EBT-XD film was much
larger than the dose calculated by integrating the activity over the time in which the film
was deployed on the phantom. A comparison of the dose measurements is shown in
Figure 80. Measurements in perfect agreement would lie on the dotted line. There are
several proposed reasons for the discrepancy in the dose measurements. The
disagreement could be due to a single cause or could be due to a combination of causes.
1. The activity of Y-90 could have been outside the 10% uncertainty quoted by
the supplier. This is unlikely. If this were the case, the overestimation of the absorbed
dose by the film would have been consistent. In communication with the vendor, the
manufacturing supervisor “was able to confirm that the dispensed activity was 97% of the
expected activity”.
2. Density differences in the aqueous solution of Y-90 chloride produced a higher
concentration of Y-90 on the bottom of the container than on the top. There is evidence
that this may have contributed to the discrepancies in dose. To check for settling of the
Y-90, the phantoms were allowed to settle for 24 hours. An aliquot was drawn near the
surface of the fluid and another aliquot was obtained at the bottom of the container. The
aliquots were equal volume. The activity in the aliquots was measured with the Wizard2
automated counting system. Each aliquot was counted for one minute with the energy
window open to capture the diffuse bremsstrahlung spectrum. For phantom 4, the aliquot
taken from the top liquid had a count rate of 681830 cpm. The aliquot taken from the
bottom of the container had a count rate of 769221 cpm. The ratio of the bottom counts
to the top counts is 1.13. The additional concentration of Y-90 at the bottom of the
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container near the film was insufficient to account for the dramatic increase in the
absorbed dose measured by the film.
3. Bremsstrahlung x-ray production in the fume hood could have led to additional
energy deposition in the film. Measurements with a survey meter showed this to be an
unlikely scenario. To shield the metal from Y-90 beta electrons, slabs of Lucite at least 1
cm thick were placed around the phantoms for the last film deployment. It did not solve
the problem.
4. The film is perhaps being over sensitized by long exposures to radiation. There
appears to be a correlation between deployment time and the degree to which the
absorbed dose is being overestimated. This trend can be seen in Figure 81. A search of
the literature did not find a mention of this effect. Similar types of radiochromic film to
EBT-XD have been in use for decades. A dramatic effect such as this that has gone
unnoticed seems unlikely.
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Delta vs Time Spent Deployed on Phantom
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Figure 81: Delta is the difference between the dose measured with the radiochromic film and the calculated
dose. Perfect agreement would have a delta of zero. There appears to be a correlation between the time
spent irradiated on the phantom and the overestimation of the absorbed dose.

5. The Sr-90/Y-90 ophthalmic applicator source activity was possibly incorrect.
The source was last calibrated in 2008. A possibility was that the source had been
damaged or altered such that the dose rate at the surface of the applicator was less than
the stated dose rate. An Elekta linear accelerator at the UNM Cancer Center was used to
irradiate five EBT-XD films with a known beam of 6 MV x-rays. The dose to the film
was determined to within a few percent. The film was allowed to stabilize for over 12
hours. A Victoreen model 07-433, Serial Number 108510 clam-shell densitometer was
used to measure the optical density (OD) of the EBT-XD film exposed by the linear
accelerator and the calibration films exposed with the Sr-90/Y-90 eye applicator. Prior to
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measurements, the calibration of the densitometer was checked with test strip Serial
Number A093364. Base plus fog measurements were also acquired of the films and
subtracted from the OD values. The results of the densitometer measurements are shown
in Figure 82. The results are in agreement. The calibration curve produced with the Sr90/Y-90 eye applicator was not the cause of the large discrepancy in the dose measured
with film.

Figure 82: Dose as a function of optical density (OD). The doses delivered to the Sr-90/Y-90 calibration
films and the films irradiated with the linear accelerator are plotted as a function of the measured optical
density.

6. The possibility that the EBT-XD was responding to visible light was
investigated. A disk of unexposed film was deployed in phantom A. This phantom had
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been loaded with water but was never loaded with Y-90. The phantom has the same
optical properties as phantom 4 and phantom 2. Prior to deploying phantom A, the other
phantoms and sources of radiation were moved out of the fume hood were the previous
film exposures had taken place. The fume hood was surveyed with a calibrated G-M
survey meter and the exposure rate was at the typical background rate of approximately
0.02 mR/hr. Phantom A was placed in the fume hood at the same location that was
occupied by phantom 4. After 24 hours, the film disk was removed from phantom A.
The optical density of the film disk was measured with the clam-shell densitometer. It
was determined that any film darkening, if present, was negligible.
7. The Y-90 yttrium chloride is bonding to the containers. The material is
shipped in glass as YCl3 in 0.04M HCl. When the acidic YCl3 is added to water, the pH
becomes more neutral and metal oxides form[83]. These metal oxides may precipitate
and adsorb on to plastic container walls. This can result in an activity concentration at
the walls and beta window several times greater than the activity concentration found in a
homogeneous mixture.
The phantoms were 500 mL Nalgene jars. The body was polycarbonate and the
lid was polypropylene. The beta window was made of Dura-lar, a commercial name for
polyethylene terephthalate (PET) polyester. The paper by Park et al. states that the metal
oxides are formed on a time scale consistent with the decay of the radionuclides [83].
Figure 84 appears to support the idea that Y-90 oxides are being created on a time scale
consistent with the half-life of Y-90 and binding to the beta window. This would result
in a measured dose greater than anticipated. In addition, all of the EBT-XD disks had
dark points spread throughout the exposed area. This non-uniformity could be indicative
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of Y-90 precipitates or localized concentrations on the beta window. Currently, the
possibility that the Y-90 metal oxides bound to the polyester beta window seems the most
likely explanation for the unexpected increase in the dose measured with the
radiochromic film.

Figure 83: Film disks D1 and D3. Dark spots are present across the entire area of the film. This indicates
the presence of localized spots of high activity on the beta window.
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Figure 84: The ratio of dose measured with film to the calculated dose is plotted as a function of the time
that elapsed since the Y-90 was added to phantom 4.

IV.

Conclusions

It has been shown that the goals of this research have been met. A surrogate
microsphere radiolabeled with F-18 has been developed that is stable in vivo. The
radiolabeling process is straightforward. The F-18 PET images can be used to perform
accurate dosimetry. If this is done prior to therapy, an improvement pre-treatment
dosimetry can be expected
The development of a positron emitting surrogate microsphere and the means to
use it in pre-treatment dosimetry can move treatment planning for Y-90
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radioembolization towards a level of accuracy that is expected in other radiation therapy
techniques such as brachytherapy and external beam therapy.

V.

Further Work

A.

Dual Energy Experiment
The clinical adoption of a surrogate particle will not happen immediately. The

ability to perform simultaneous administration of F-18 microspheres and Tc-99m MAA
may be worth investigating. Preliminary investigations have found that the relatively
low-energy 140 keV gamma photons from the decay of Tc-99m do not affect the PET
image. This is expected since the energy window for PET imaging is set much higher
than 140 keV.
The question remains as to how much F-18 can be in the gamma camera FOV
without perturbing the lung shunt measurements. The current strategy is to make a
scatter window that will measure the amount of annihilation photons from F-18 that
downscatter into the Tc-99m energy window. This scatter energy window is
approximately the same size as the Tc-99m window and is set to a higher energy than the
Tc-99m window. For SPECT imaging the default Tc-99m window used is 15%. The
lung shunt fraction is a ratio of relative activities measured in the lungs and the liver. In
the presence of F-18, it is not entirely clear how the downscatter may affect the counts in
the Tc-99m energy window when the ROI are in two different anatomic positions.
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B.

Modify Beta Dosimetry System
It would be useful to perform the Y-90 dosimetry measurements again. Several

options need to be examined prior to repetition of the experiment. These include
modification of the phantom to reduce and replace materials likely to bond to Y-90 metal
oxides. The addition of a chelator such as EDTA should be considered. Another
possibility is to replace the 400 mL of water with an equal volume of 0.04 M HCl acid.
This is the same acid concentration used for shipping of the [Y-90] YCl3. Imaging of the
phantom at the several time points could be very useful as well. Imaging can be used to
confirm that the activity concentration in the Y-90 solution is remaining homogeneous or
not.

C.

In Vivo Testing in a Larger Animal
It would be worthwhile to perform in vivo testing in an animal larger than a rat.

In this scenario, a catheter would be inserted into the femoral artery for injection of F-18
radiolabeled hydroxyapatite microspheres directly into the liver. This would enable the
study of the interaction between macrophages of the liver and the radiolabeled
microspheres.

VI.

Beyond the Scope of This Work

Clinical trials with human subjects are beyond the scope of this work.
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